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A B S T R A C T
Background
The review represents one in a family of four reviews focusing on a range of different interventions for drug-using offenders. This
specific review considers pharmacological interventions aimed at reducing drug use or criminal activity, or both, for illicit drug-using
offenders.
Objectives
To assess the effectiveness of pharmacological interventions for drug-using offenders in reducing criminal activity or drug use, or both.
Search methods
We searched Fourteen electronic bibliographic databases up to May 2014 and five additional Web resources (between 2004 and
November 2011). We contacted experts in the field for further information.
Selection criteria
We included randomised controlled trials assessing the efficacy of any pharmacological intervention a component of which is designed
to reduce, eliminate or prevent relapse of drug use or criminal activity, or both, in drug-using offenders. We also report data on the
cost and cost-effectiveness of interventions.
Data collection and analysis
We used standard methodological procedures as expected by Cochrane.
Main results
Fourteen trials with 2647 participants met the inclusion criteria. The interventions included in this review report on agonistic pharma-
cological interventions (buprenorphine, methadone and naltrexone) compared to no intervention, other non-pharmacological treat-
ments (e.g. counselling) and other pharmacological drugs. The methodological trial quality was poorly described, and most studies were
rated as ’unclear’ by the reviewers. The biggest threats to risk of bias were generated through blinding (performance and detection bias)
and incomplete outcome data (attrition bias). Studies could not be combined all together because the comparisons were too different.
Only subgroup analysis for type of pharmacological treatment were done. When compared to non-pharmacological, we found low
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quality evidence that agonist treatments are not effective in reducing drug use or criminal activity, objective results (biological) (two
studies, 237 participants (RR 0.72 (95% CI 0.51 to 1.00); subjective (self-report), (three studies, 317 participants (RR 0.61 95% CI
0.31 to 1.18); self-report drug use (three studies, 510 participants (SMD: -0.62 (95% CI -0.85 to -0.39). We found low quality of
evidence that antagonist treatment was not effective in reducing drug use (one study, 63 participants (RR 0.69, 95% CI 0.28 to 1.70)
but we found moderate quality of evidence that they significantly reduced criminal activity (two studies, 114 participants, (RR 0.40,
95% CI 0.21 to 0.74).
Findings on the effects of individual pharmacological interventions on drug use and criminal activity showed mixed results. In the
comparison of methadone to buprenorphine, diamorphine and naltrexone, no significant differences were displayed for either treatment
for self report dichotomous drug use (two studies, 370 participants (RR 1.04, 95% CI 0.69 to 1.55), continuous measures of drug use
(one study, 81 participants, (mean difference (MD) 0.70, 95% CI -5.33 to 6.73); or criminal activity (one study, 116 participants, (RR
1.25, 95% CI 0.83 to 1.88) between methadone and buprenorphine. Similar results were found for comparisons with diamorphine
with no significant differences between the drugs for self report dichotomous drug use for arrest (one study, 825 participants, (RR 1.25,
95% CI 1.03 to 1.51) or naltrexone for dichotomous measures of reincarceration (one study, 44 participants, (RR 1.10, 95% CI 0.37
to 3.26), and continuous outcome measure of crime, (MD -0.50, 95% CI -8.04 to 7.04) or self report drug use (MD 4.60, 95% CI -
3.54 to 12.74).
Authors’ conclusions
When compared to non-pharmacological treatment, agonist treatments did not seem effective in reducing drug use or criminal activity.
Antagonist treatments were not effective in reducing drug use but significantly reduced criminal activity. When comparing the drugs to
one another we found no significant differences between the drug comparisons (methadone versus buprenorphine, diamorphine and
naltrexone) on any of the outcome measures. Caution should be taken when interpreting these findings, as the conclusions are based
on a small number of trials, and generalisation of these study findings should be limited mainly to male adult offenders. Additionally,
many studies were rated at high risk of bias.
P L A I N L A N G U A G E S U M M A R Y
Pharmacological interventions for drug-using offenders
Background
Drug-using offenders by their nature represent a socially excluded group in which drug use is more prevalent than in the rest of the
population. Pharmacological interventions play an important role in the rehabilitation of drug-using offenders. For this reason, it is
important to investigate what we know works when pharmacological interventions are provided for offenders.
Study characteristics
The review authors searched scientific databases and Internet resources to identify randomised controlled trials (where participants are
allocated at random to one of two or more treatment groups) of interventions to reduce, eliminate, or prevent relapse of drug use or
criminal activity of drug-using offenders. We included males and female of any age or ethnicity.
Key results
We identified 14 trials of pharmacological interventions for drug-using offenders. The interventions included: (1) naltrexone in
comparison with routine parole, social psychological treatment or both; (2) methadone maintenance in comparison with different
counselling options; and (3) naltrexone, diamorphine and buprenorphine in comparison with a non-pharmacological alternative and
in combination with another pharmacological treatment. Studies could not be combined all together because the comparisons were too
different. When compared to non-pharmacological, we found low quality evidence that agonist treatments are not effective in reducing
drug use or criminal activity . We found low quality of evidence that antagonist treatment was not effective in reducing drug use but
we found moderate quality of evidence that they significantly reduced criminal activity. When comparing the drugs to one another
we found no significant differences between the drug comparisons (methadone versus buprenorphine, diamorphine and naltrexone)
on any of the outcome measures suggesting that one pharmacological drug does not preside over another. One study provided some
cost comparisons between buprenorphine and methadone, but data were not sufficient to generate a cost-effectiveness analysis. In
conclusion, we found that pharmacological interventions do reduce subsequent drug use and criminal activity (to a lesser extent).
Additionally, we found individual differences and variation between the degree to which successful interventions were implemented
and were able to sustain reduction of drug use and criminal activity.
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Quality of evidence
This review was limited by the lack of information reported in this group of trials and the quality of the evidence was low. The evidence
is current to May 2014.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Agonist pharmacological compared to no intervention for drug-using offenders
Patient or population: drug-using offenders
Settings: criminal justice
Intervention: Agonist pharmacological
Comparison: no intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No intervention Agonist pharmacologi-
cal
Drug use (objective)
hair and urine analyses
Follow-up: 3 months to 4
years
Study population RR 0.72
(0.51 to 1)
237
(2 studies)
⊕⊕©©
low1,2
43 per 100 31 per 100
(22 to 43)
Moderate
50 per 100 36 per 100
(25 to 50)
Drug use self reported
dichotomous
self report information
Follow-up: 3 months to 4
years
Study population RR 0.61
(0.31 to 1.18)
317
(3 studies)
⊕⊕©©
low3,4
74 per 100 45 per 100
(23 to 88)
Moderate
74 per 100 45 per 100
(23 to 88)
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Drug use self reported
continuous
self report information
Follow-up: 9 months to 4
years
The mean drug use self
reported continuous in the
intervention groups was
0.62 standard deviations
lower
(0.85 to 0.39 lower)
510
(3 studies)
⊕⊕©©
low5,6
SMD -0.62 (-0.85 to -0.
39)
Criminal activity di-
chotomous - Arrests
official records
Follow-up: median 9
months
Study population RR 0.6
(0.32 to 1.14)
62
(1 study)
⊕⊕©©
low7,10
55 per 100 33 per 100
(18 to 63)
Moderate
55 per 100 33 per 100
(18 to 63)
Criminal activity di-
chotomous - Re-incar-
ceration
official records
Follow-up: 7 months to 4
years
Study population RR 0.77
(0.36 to 1.64)
472
(3 studies)
⊕⊕©©
low8,9
66 per 100 51 per 100
(24 to 100)
Moderate
83 per 100 64 per 100
(30 to 100)
Criminal activity contin-
uous
mean number of crime
dayes
Follow-up: median 9
months
The mean criminal activ-
ity continuous in the in-
tervention groups was
74.21 lower
(133.53 to 14.89 lower)
51
(1 study)
⊕⊕©©
low 7,11
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Across the two studies 10 of the 18 risk of bias items in total were rated as unclear.
2 The total number of events across the two studies is less than 300. This is a threshold rule of thumb based on Muller et al Ann Intern
Med. 2007; 146: 878-881.
3 Across the three studies 17 items were rated as unclear out of a total of 27 items.
4 The P value for heterogenity is less than 0.05 and the I2 is 89% suggesting significant inconsistency between the studies.
5 Across the three studies 16 of the 27 items on risk of bias were rated as unclear
6 The P value for heterogenity is less than 0.05 and the I2 is 99% suggesting significant inconsistency across the studies.
7 6 of the 9 risk of bias items were rated as unclear
8 Across the three studies 17 of the 27 risk of bias items in total were rated as unclear
9 The P value for heterogenity is less than 0.05 and the I2 is 74% suggesting significant heterogenity.
10 only 1 study with 62 participants
11 only 1 study with 51 participants
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B A C K G R O U N D
This review represents part of a family of four reviews undertaken
to closely examine what works in reducing drug use and crimi-
nal activity among drug-using offenders. Overall, the four reviews
contain over 100 trials, generating a number of publications and
numerous comparisons (Perry 2013a; Perry 2013b; Perry 2013c).
The four reviews represent specific interests in pharmacological in-
terventions, non-pharmacological interventions, female offenders
and offenders with co-occurring mental illness. All four reviews
stem from an updated previous Cochrane systematic review (Perry
2006). In this set of four reviews, we consider the effectiveness
of interventions based on two key outcomes and analyse the im-
pact of setting and intervention type. Presented here is the revised
methodology for this individual review, focusing on the impact of
pharmacological interventions provided for drug-using offenders.
Description of the condition
Offenders as a socially excluded group of people demonstrate sig-
nificant drug use and subsequent health problems. Studies inves-
tigating the prevalence of drug dependence in UK prisons report
variable results of 10% (Gunn 1991), 39% (Brooke 1996), and
33% (Mason 1997). Similar trends have been reported elsewhere.
In France, 30% of prison inmates are heroin addicted, and in Aus-
tralia, 59% of prison inmates report injecting (primarily heroin)
drug use histories. In the US, it is recognised that many offenders
are in need of treatment to tackle their drug use (Lo 2000).The
link between drug use, subsequent health and social and crimi-
nological consequences is well documented in the literature (e.g.
Michel 2005), and offenders have a high risk of death from opi-
oid overdose within two weeks of release from incarceration (Bird
2003; Binswanger 2007). Substance use disorders are linked to
criminal behaviour and are a significant burden on the criminal
justice system. Approximately 30% of acquisitive crime is com-
mitted by individuals supporting drug use with the use of criminal
acts (Magura 1995).
Description of the intervention
Internationally, methadone maintenance has been the primary
choice for chronic opioid dependence in prisons and jails, includ-
ing those in the Netherlands, Australia, Spain and Canada, and it
is being increasingly implemented in the criminal justice setting
(Moller 2007; Stallwitz 2007). The US has not generally endorsed
the use of methadone treatment, and only 12% of correctional
settings offer this option for incarcerated inmates (Fiscella 2004).
Reasons for this lack of expansion suggest that public opinion
and that of criminal justice system providers consider methadone
treatment as substituting one addiction for another. In contrast,
buprenorphine appears not to carry the same social stigma asso-
ciated with methadone treatment and has been used in France,
Austria and Puerto Rico (Catania 2003; Reynaud-Maurupt 2005;
Garcia 2007). Naltrexone treatment has shown some promising
findings, but associated problems surrounding high attrition and
low medication compliance in the community and high mortality
rates (e.g. Gibson 2007; Minozzi 2011) pose concerns. Trials con-
ducted in the criminal justice setting are still lacking, and continu-
ity of care is considered crucial in the treatment of drug-involved
offenders who transition between prison and the community.
How the intervention might work
A growing body of evidence shows the effects of pharmacological
interventions for drug use among the general population. Exist-
ing reviews have focused on naltrexone maintenance treatment
for opioid dependence (Amato 2005; Lobmaier 2008; Minozzi
2011); and the efficacy of methadone (Marsch 1998; Faggiano
2003; Mattick 2009); and buprenorphine maintenance (Mattick
2009). Recent guidance has been provided from the National In-
stitute forHealth and Clinical Excellence on evidence-based use of
naltrexone,methadone and buprenorphine for themanagement of
opioid dependence (NICE 2007a; NICE 2007b). Five Cochrane
reviews (including 52 studies) reported on the effectiveness of
opiate methadone therapies (Amato 2005). Findings showed that
methadone maintenance therapies at appropriate doses were most
effective in retaining participants in treatment and in suppressing
heroin use, but evidence of effectiveness for other relevant out-
come measures such as criminal activity was weak and was not
systematically evaluated.
Systematic reviews evaluating treatment programs more generally
for offender populations have focused on evaluating treatment in
one setting such as community-based programmes, (e.g. Mitchell,
2012a;Mitchell, 2012b); or have based their evidence on literature
from one country (e.g. Germany or the US) (Chanhatasilpa 2000;
Egg 2000); or a number of specific treatments (Mitchell 2006).
Pharmacological systematic reviews of offender treatment appear
to be sparse. We identified two previous reviews, one focusing on
specific drug- and property-related criminal behaviours in meth-
adone maintenance treatment (Marsch 1998); and an evaluation
of the effectiveness of opioid maintenance treatment (OMT) in
prison and post-release (Hedrich 2011). The later of these two
reviews identified six experimental studies up until January 2011
(Hedrich 2011). The authors found that OMT in prison was sig-
nificantly associatedwith reduced heroin use, injecting and syringe
sharing. Use of pre-releaseOMTwas also found to have important
implications for associated treatment uptake after release, but the
impact on criminal activity was equivocal.
Why it is important to do this review
The current review provides a systematic examination of trial ev-
idence relating to the effectiveness of pharmacological interven-
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tions for drug-using offenders. We believe it is important to con-
duct this review because the evidence about pharmacological in-
terventions for drug-using offenders has not been evaluated in this
manner before. In order to address this broad topic a series of
questions will consider the effectiveness of different interventions
in relation to criminal activity, drug misuse treatment setting and
type of treatment. The review will additionally report descriptively
on the costs and cost effectiveness of such treatment programs.
O B J E C T I V E S
To assess the effectiveness of pharmacological interventions for
drug-using offenders in reducing criminal activity or drug misuse
or both. The review addressed the following questions:
• Does any pharmacological treatment for drug-using
offenders reduce drug use?
• Does any pharmacological treatment for drug-using
offenders reduce criminal activity?
• Does the treatment setting (e.g. court, community, prison/
secure establishment) affect outcome(s) of pharmacological
treatments?
• Does one type of pharmacological treatment perform better
than one other?
Additionally, this review aimed to report on the cost and cost-
effectiveness of interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs)
Types of participants
We included illicit drug-misusing offenders in the review regard-
less of gender, age, ethnicity or psychiatric illness. Drug misuse
includes individuals occasionally using drugs, or who are depen-
dent on, or are known to abuse, drugs. Offenders are defined as
individuals who were subject to the criminal justice system.
Types of interventions
Included interventions were designed, wholly or in part, to elim-
inate or prevent relapse to drug use or criminal activity, or both,
among participants. We defined relapse as individuals who may
have returned to an incarcerated setting, or had subsequently been
arrested or had relapsed back into drug misuse, or both. We in-
cluded a range of different types of interventions in the review.
Experimental interventions included in the review:
• Any pharmacological intervention (e.g. buprenorphine,
methadone)
Control interventions included in the review.
• No treatment
• Minimal treatment
• Waiting list
• Treatment as usual
• Other treatment (e.g. pharmacological or psychosocial)
Types of outcome measures
Primary outcomes
For the purpose of our review we categorised our primary out-
comes into those relating to dichotomous and continuous drug
use or criminal activity, or both. Where papers reported a number
of different follow-up periods, we report the longest time period,
as we felt that such measures provide the most conservative esti-
mate of effectiveness. For specific meta-analyses of sub-groupings,
we reviewed all reported follow-up periods to select the most ap-
propriate time period for combining comparable studies.
• Drug use measures were reported as:
◦ self-report drug use (unspecified drug, specific drug
use not including alcohol/tobacco, Addiction Severity Index
drug composite scores); and
◦ biological drug use (measured by drugs tested by urine
or hair analysis).
• Criminal activity as measured by:
◦ self-report or official report of criminal activity
(including arrest for any offence, drug offences, reincarceration,
convictions, charges and recidivism).
Secondary outcomes
Our secondary outcome reported on costs or cost-effectiveness
information. We used a descriptive narrative for these findings.
We undertook a full critical appraisal based on the Drummond
1997 checklist for those studies presenting sufficient information.
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Search methods for identification of studies
Electronic searches
Electronic searches
The update searches identified records from 2004 to May 2014.
• CENTRAL (Issue 5, 2014).
• MEDLINE (1966 to May 2014).
• EMBASE (1980 to May 2014).
• PsycINFO (1978 to April 2014).
• Pascal (1973 to November 2004)a .
• SciSearch (Science Citation Index) (1974 to April 2014).
• Social SciSearch (Social Science Citation Index) (1972 to
April 2014).
• ASSIA (1987 to May 2014).
• Wilson Applied Science and Technology Abstracts (1983 to
October 2004)a .
• Inside Conferences (1993 to November 2004)a .
• Dissertation Abstracts (1961 to October 2004)a .
• NTIS (1964 to April 2014).
• Sociological Abstracts (1963 to April 2014).
• HMIC (to April 2014).
• PAIS (1972 to April 2014).
• SIGLE (1980 to June 2004)b .
• Criminal Justice Abstracts (1968 to April 2014).
• LILACS (2004 to April 2014).
• National Research Register (March 2004)c .
• Current Controlled Trials (December 2009).
• Drugscope (February 2004) unable to access.
• SPECTR (March 2004)d .
aUnable to access further to 2004 search.
bDatabase not updated since original 2004 search.
cNo longer exists.
dNow Campbell Collaboration searched on line.
To update the original review (Perry 2006), the search strategy
was restricted to studies that were published or unpublished from
2004 onwards. A number of original databases were not searched
for this update (indicated by the key at the end of the database
list). Pascal, ASSIA, Wilson Applied Science and Technology Ab-
stracts, Inside Conferences and Dissertation Abstracts were not
searched. These databases are available only via the fee-charging
DIALOG online host service: we did not have the resources to un-
dertake these searches. The National Research Register no longer
exists, and SIGLE has not been updated since 2005. Drugscope is
available only to subscribing members. The original searches were
undertaken by Drugscope staff.
Search strategies were developed for each database to exploit the
search engine most effectively and to make use of any controlled
vocabulary. Search strategies were designed to restrict the results
to RCTs. No language restriction was placed on the search results.
We included methodological search filters designed to identify tri-
als. Whenever possible, filters retrieved from the InterTASC In-
formation Specialists’ Sub-Group (ISSG) Search Filter Resource
site (http://www.york.ac.uk/inst/crd/intertasc/) were used. If fil-
ters were unavailable from this site, search terms based on existing
filters were used instead.
In addition to the electronic databases, a range of relevant Inter-
net sites (Home Office, National Institute of Drug Abuse (NIDA)
and European Association of Libraries and Information Services
on Alcohol and Other Drugs (ELISAD)) were searched. Direc-
tory web sites, including OMNI (http://www.omni.ac.uk), were
searched up until November 2011. The review did not place any
language restrictions on identification and inclusion of studies in
the review.
Details of the update search strategies and results and of the Inter-
net sites searched are listed in Appendix 1; Appendix 2; Appendix
3; Appendix 4; Appendix 5; Appendix 6; Appendix 7; Appendix 8;
Appendix 9; Appendix 10; Appendix 11; Appendix 12; Appendix
13.
Searching other resources
Reference checking
We scrutinised the reference lists of all retrieved articles for fur-
ther references, and also undertook searches of the catalogues of
relevant organisations and research founders.
Personal communication
We contacted experts for their knowledge of other studies, pub-
lished or unpublished, relevant to the review.
Data collection and analysis
Selection of studies
Twoauthors independently inspected the search hits by reading the
titles and abstracts, and obtained each potentially relevant study
located in the search as a full-text article to independently assess
them for inclusion. In the case of discordance, a third independent
author arbitrated. One author undertook translation of articles
not written in the English language.
The screening process was divided into two key phases. Phase one
used the initial seven key questions reported in the original new
reference review. These were:
Prescreening criteria: phase one
• Is the document an empirical study? [If “no” exclude
document.]
• Does the study evaluate an intervention, a component of
which is designed to reduce, eliminate or prevent relapse among
drug-using offenders?
• Are the participants referred by the criminal justice system
at baseline?
• Does the study report pre-programme and post-programme
measures of drug use?
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• Does the study report pre-programme and post-programme
measures of criminal behaviour?
• Is the study a randomised controlled trial?
• Do the outcome measures refer to the same length of
follow-up for two groups?
After relevant papers from phase one had been identified, phase
two screening was performed to identify papers reporting on phar-
macological interventions. Criteria included the following.
Prescreening: phase two
• Is the intervention a pharmacological intervention? [if “yes”
include document]
Drug-using interventions were implied if the programme targeted
reduced drug use in a group of individuals. Offenders were indi-
viduals either residing in special hospitals, prisons, the community
(i.e. under the care of the probation service) or diverted from court
or placed on arrest referral schemes for treatment. We included
studies in the review where the sample were not entirely drug-us-
ing, but reported pre- and post-measures. The study setting could
change throughout the process of the study, e.g. offenders could
begin in prison but progress through a work-release project into
a community setting. Finally, studies did not need to report both
drug and criminal activity outcomes: if either of these was reported
we included the study in the review.
Data extraction and management
We used data extraction forms to standardise the reporting of
data from all studies obtained as potentially relevant. Two authors
independently extracted data and subsequently checked them for
agreement.
Assessment of risk of bias in included studies
Five independent review authors (AEP, JMG, MM-SJ, MN, RW)
assessed risk of bias in all included studies using risk of bias assess-
ment criteria recommended in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011).
The risk of bias assessment for RCTs in this review was performed
using the criteria recommended by the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). The recom-
mended approach for assessing risk of bias in studies included in
a Cochrane Review involves the use of a two-part tool that ad-
dresses six specific domains, namely, sequence generation and al-
location concealment (selection bias), blinding of participants and
providers (performance bias), blinding of outcome assessor (de-
tection bias), incomplete outcome data (attrition bias), selective
outcome reporting (reporting bias), and other sources of bias. The
first part of the tool involves describing what was reported to have
happened in the study. The second part of the tool involves assign-
ing a judgement related to the risk of bias for that entry in terms of
low, high or unclear risk. To make these judgements, we used the
criteria indicated by theCochrane Handbook for Systematic Reviews
of Interventions as adapted for the addiction field.
The domains of sequence generation and allocation concealment
(avoidance of selection bias) were addressed in the tool by a single
entry for each study.
Blinding of participants, personnel and outcome assessor (avoid-
ance of performance bias and detection bias) was considered sep-
arately for objective outcomes (e.g. dropping out, using substance
of abuse as measured by urinalysis, relapsing of participants at
the end of follow-up, engaging of participants in further treat-
ments) and subjective outcomes (e.g. duration and severity of signs
and symptoms of withdrawal, participant self-reported use of sub-
stance, side effects, social functioning as integration at school or
at work, family relationships).
Incomplete outcome data (avoidance of attrition bias) were con-
sidered for all outcomes except dropping out of treatment, which
very often is the primary outcome measure in trials on addiction.
See Appendix 14 for details.
For studies identified in the most recent search, the review authors
attempted to contact study authors to establish whether a study
protocol was available.
Measures of treatment effect
The mean differences (MD) were used for outcomes measured
on the same scale and the standardised mean difference (SMD)
for outcomes measured on different scales. Higher scores for con-
tinuous measures are representative of greater harm. We present
dichotomous outcomes as risk ratios (RR), with 95% confidence
intervals (CIs).
Unit of analysis issues
To avoid double counting of outcome measures (e.g. arrest and
parole violation) and follow up time periods (e.g. 12, 18 months)
all trials were checked to ensure that multiple studies reporting
the same evaluation did not contribute towards multiple estimates
of programme effectiveness. We followed Cochrane guidance and
where appropriate we combined intervention and control groups
to create a single pairwise comparison. Where this was not appro-
priate we selected one treatment arm and excluded the others.
Dealing with missing data
Where we found data was missing in the original publication, we
attempted to contact the study authors via email to obtain the
missing information.
Assessment of heterogeneity
Heterogenity was assessed using I² andQ statistics (Higgins 2011).
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Data synthesis
The RevMan software package was used to perform a series of
meta-analyses for continuous and dichotomous outcomemeasures
(Review Manager 2014). A random-effects model was used to ac-
count for the fact that participants did not come from a single un-
derlying population. A narrative review were performed to address
each of the key questions outlined in the objectives. The narrative
tables included a presentation of study details (e.g. author, year
of publication, and country of study origin), study methods (e.g.
random assignment), participants (e.g. number in sample, age,
gender, ethnicity, age, mental health status), interventions (e.g. de-
scription, duration, intensity, setting), outcomes (e.g. description,
follow-up period, reporting mechanism), resource and cost infor-
mation and resource savings (e.g. number of staff, intervention de-
livery, estimated costs, estimated savings), and notes (e.g. method-
ological and quality assessment information). For outcomes of
criminal activity, data were sufficient to allow the review authors to
divide this activity into “re-arrest” and reincarceration categories.
Subgroup analysis and investigation of heterogeneity
A separate subgroup analysis of the studieswas plannedby different
types of treatments and different settings.
Sensitivity analysis
When appropriate, sensitivity analyses were planned to assess the
impact of studies with high risk of bias. Because of the overall high
risk of bias of the included studies, this analysis was not conducted.
R E S U L T S
Description of studies
Results of the search
Original review
The original searches spanned from database inception toOctober
2004. This identified a total of 8217 records after duplication. We
acquired a total of 90 full text papers for assessment and excluded
66 papers, bringing 24 trials to the review (see Figure 1).
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Figure 1. Study flow diagram of paper selection: Original Review
First update
The updated searches spanned from October 2004 until March
2013. This identified a total of 3896 records after duplication. We
acquired a total of 115 full text papers for assessment and excluded
105 papers, bringing 10 new trials to the review (see Figure 2).
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Figure 2. Study flow diagram of paper selection: First Update
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Second update
The updated searches spanned fromMarch 2013 until May 2014.
This identified a total of 2092 records after duplication. We ac-
quired a total of 72 full text papers for assessment and excluded
68 papers, bringing four new trials to the review making a total of
14 trials (see Figure 3).
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Figure 3. Study flow diagram of paper selection: Second Update
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Included studies
• The studies were published between 1969 and 2014 and
represented 14 trials, including 2647 participants. The 14 trials
consisted of 18 trial publications on different interventions
(Bayanzadeh 2004; Brown 2013; Cornish 1997; Cropsey 2011;
Coviello 2010; Dolan 2003; Dole 1969; Howells 2002; Kinlock
2005; Kinlock 2007; Lobmaier 2010; Lobmann 2007; Magura
2009; Wright 2011). Two trials represented data from multiple
follow-up publications. The Dolan studies published data on the
primary study and four year follow-up data (Dolan 2003); and
Kinlock and colleagues reported on outcome measures and a
secondary analysis of the data in two subsequent publications
(see Kinlock 2007). See Table 1 for a summary of study
information and outcomes.
• A number of studies produced different comparisons and
were combined appropriately according to time point of
measurement (e.g. 1 month, 3 months, 6 months, 12 months)
and type of outcome.
Treatment regimens and settings
• Thirteen studies used methadone as the intervention or for
comparison (Bayanzadeh 2004; Brown 2013; Dolan 2003; Dole
1969; Howells 2002; Kinlock 2005; Kinlock 2007; Lobmaier
2010; Lobmann 2007; Magura 2009; Wright 2011). Brown
2013 compared specialist treatment plus suboxone or methadone
versus primary care plus suboxone; Lobmann 2007 compared
methadone with diamorphine; and Magura 2009 and Wright
2011 compared methadone with buprenorphine. One study
compared methadone to lofexidine (Howells 2002). All other
studies compared methadone maintenance with interventions
where there was no drugs administration (waiting list or
counselling alone).
• Three studies used naltrexone in oral and implantation
formats in comparison with probation or parole (Cornish 1997);
psychosocial therapy (Coviello 2010); and methadone (Lobmaier
2010).
• One study compared the use of buprenorphine with a
placebo (Cropsey 2011).
• The studies were categorised by setting; five studies were
conducted in the community (Cornish 1997; Lobmann 2007;
Coviello 2010; Cropsey 2011; Brown 2013); and the remainder
in secure settings (Dole 1969; Dolan 2003; Bayanzadeh 2004;
Kinlock 2005; Kinlock 2007; Magura 2009; Lobmaier 2010;
Howells 2002; Wright 2011).
• One study was conducted using a jail diversion scheme for
either a drug treatment court or Treatment Alternative Program
(TAP) (Brown 2013).
• Different outcome measures were presented for each study,
and just over half of all studies reported four or more outcome
measures (see Table 1). Criminal justice and drug outcomes were
measured by all studies except four. Cornish 1997 and Lobmann
2007 reported on criminal activity outcomes only; and
Bayanzadeh 2004, Brown 2013, Dolan 2003, Cropsey 2011 and
Wright 2011 reported on drug use only.
Countries in which the studies were conducted
• Nine studies were published in the US, two in England, one
in Iran, one in Australia, one in Norway and one in Germany.
Duration of trials
• Most studies (n = 10) reported outcomes of six months or
less, and the longest follow-up period was four years.
Participants
• The fourteen studies included adult drug-using offenders:
twelve of the fourteen studies used samples with a majority of
men and one study used female offenders only (Cropsey 2011).
In two studies, gender was not reported (Lobmann 2007; Wright
2011).
• The average age of study participants ranged from 27 years
to 40.9 years.
Excluded studies
We excluded 165 studies. See Characteristics of excluded studies
for further details. Reasons for exclusion were: lack of criminal
justice involvement in referral to the intervention; not reporting
relevant drug or crime outcome measures or both at both the pre-
and post-intervention periods; allocation of participants to study
groups that were not strictly randomised or did not contain orig-
inal trial data. The majority of studies were excluded because the
study population were not offenders. One study was excluded be-
cause follow-up periods were not equivalent across study groups
(Di Nitto 2002); and Berman 2004 was excluded because the in-
tervention (acupuncture) did not measure our specified outcomes
of drug use or criminal activity. One study reported the protocol
of a trial only (Baldus 2011); while another only contained con-
ference proceedings (Kinlock 2009a). We were unable to obtain
the data for one trial (Cogswell 2011); or the full-text version of
another (Rowan-Szal 2005).
Risk of bias in included studies
See Figure 4 and Figure 5 for further information.
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Figure 4. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 5. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Randomisation: All of the 14 included studies were described as
randomised. In four studies, the reporting of this information was
noted as unclear, as it was difficult to find an accurate description
of the methodology used (Brown 2013; Coviello 2010; Howells
2002; Kinlock 2005). Two studies were reported at high risk of
bias (Bayanzadeh 2004; Cropsey 2011); and the remaining eight
studies at low risk of bias.
Allocation concealment: Of the 14 included studies, only four
reported that the allocation process was concealed and were rated
at low risk of bias (Cropsey 2011; Dolan 2003; Lobmaier 2010;
Wright 2011). One study was rated at high risk of bias (Magura
2009). All of the remaining nine studies were rated as unclear,
and the review author was not able to decide whether allocation
concealment had occurred within the studies.
Blinding
Blinding was assessed across four dimensions considering perfor-
mance and detection bias across subjective and objective mea-
sures (see Appendix 14). Nine studies were rated as unclear risk
of bias providing no information on blinding across all four do-
mains (Bayanzadeh 2004; Brown 2013; Cropsey 2011; Dolan
2003; Dole 1969; Kinlock 2005; Kinlock 2007; Lobmann 2007;
Magura 2009). Four studies were rated at high risk of bias for par-
ticipant and personnel blinding (Cornish 1997; Coviello 2010;
Lobmaier 2010; Wright 2011). Cornish 1997 was rated at low
risk of outcome assessors on objective measures.
Incomplete outcome data
Four studies were noted at low risk of bias (Cornish 1997; Dole
1969; Lobmaier 2010; Lobmann 2007); eight studies were noted
at high risk of bias; and two studies were rated as unclear (Cropsey
2011; Magura 2009).
Selective reporting
Of the 14 studies, nine studies were rated as unclear, and two
studies were rated at low risk (Dolan 2003; Howells 2002). Three
studies were rated at high risk of bias (Brown 2013; Kinlock 2005;
Wright 2011).
Other potential sources of bias
Threats to other bias within the study designs generally yielded
mixed results. In total, seven studies were rated at high risk. Low
risk was noted in four further studies (Cropsey 2011; Dolan 2003;
Lobmaier 2010; Wright 2011); and three studies were rated as
unclear (Cornish 1997; Dole 1969; Lobmann 2007).
See Figure 4 and Figure 5 for additional details.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings for the main comparisons: Agonist pharmacological
compared to no intervention for drug-using offenders; Summary
of findings 2 Summary of findings for the main comparisons:
Antagonost (Naltrexone) compared to no pharmacological for
drug-using offenders
Of the 14 studies, 11 were included in a series of meta-analyses and
the main comparisons are presented in the ’Summary of findings’
tables (Summary of findings for the main comparison; Summary
of findings 2). Three studies were not included in the meta-anal-
yses: Bayanzadeh 2004 because it compared methadone + CBT
versus not further specified non-pharmacological treatment, so it
was not possible to ascertain the effect of methadone treatment
alone; Brown 2013 because it compared specialist treatment plus
suboxone or methadone versus primary care plus suboxone, so it
was not possible to ascertain the effect of methadone or suboxone
alone; moreover it did not assess the outcomes of interest; and
Howells 2002 because it did not assess the outcomes of interest
and repeated attempted contact with the authors asking for more
information was unsuccesful. For those studies that were included
we grouped them by drug and criminal activity outcomes (re-ar-
rest and reincarceration), setting (community and secure estab-
lishment), and intervention type (buprenorphine, methadone and
naltrexone). Tests for heterogeneity at the 0.01 level revealed that
across all meta-analyses, the studies were found to be homoge-
neous.
1. Agonist pharmacological interventions vs no non-
pharmacological treatment
Drug use
See Summary of findings for the main comparison
For dichotomous measure, results did not show reduction in drug
use for objective results (biological), two studies, 237 participants:
(RR 0.72, 95% CI 0.51 to 1.00), low quality of evidence and for
subjective (self-report), three studies, 317 participants: (RR 0.61
95% CI 0.31 to 1.18), low quality of evidence. Also for continu-
ous measures, self-report drug use did not show differences, three
studies, 510 participants: (SMD -0.62 95% CI -0.85 to -0.39),
low quality of evidence, see Analysis 1.1; Analysis 1.2; andAnalysis
1.3.
Criminal activity
See Summary of findings for the main comparison
All data come from studies assessing the efficacy of methadone
treatment. Both for reincarceration three studies, 472 participants
(RR 0.77, 95% CI 0.36 to 1.64) low quality of evidence; and re-
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arrests, one study, 62 participants (RR0.60, 95%CI 0.32 to 1.14),
low quality of evidence, the studies did not show difference (see
Analysis 1.4). The impact on criminal activities was evaluated also
utilising continuous measures in one study, 51 participants: MD
of -74.21 (95%CI -133.53 to -14.89), low quality of evidence, the
result is in favour of pharmacological interventions, (see Analysis
1.5).
2. Antagonist (Naltrexone) pharmacological
treatment vs non -pharmacological treatment?
See Summary of findings 2
Two studies, 114 participants focused on the use of naltrexone
versus no pharmacological treatment and subsequent criminal ac-
tivity. The results indicate that naltrexone does appear to reduce
subsequent reincarceration, with an RR of 0.40 (95% CI 0.21,
0.74), moderate quality of evidence, see Analysis 2.1
One study, 63participants (RR0.69, 95%CI0.28 to 1.70) did not
show statistically significant difference, low quality of evidence,
see Analysis 2.2,
3. Methadone versus buprenorphine
Drug use
Two studies (Magura 2009; Wright 2011), showed a reduction
in self report drug use for 370 participants using a dichotomous
outcome (RR 1.04. 95% CI 0.69 to 1.55) altough the result is not
statistically significant. Continuous outcomes, one study with 81
participants, (MD 0.70, 95% CI -5.33 to 6.73) see Analysis 3.1
and Analysis 3.2 .
Criminal activity
Magura 2009 showed a non-statistically significant reduction in
criminal activity for 116 participants (RR 1.25, 95% CI 0.83 to
1.88) see Analysis 3.3.
4. Methadone versus diamorphine
Drug use: the study did not assess this outcome
Criminal activity
Rearrest: One study, (Lobmann 2007) 825 participants shows a
non-statistically significant reduction in criminal activity for re-
arrests: (RR 1.25, 95% CI 1.03 to 1.51 see Analysis 4.1.
5. Methadone vs naltrexone
Drug use
Lobmaier 2010, 44 participants, showed a non-statistically sig-
nificant reduction in self reported drug use continuous MD 4.60
(95% CI -3.54 to 12.74) see Analysis 5.1.
Criminal activity
Lobmaier 2010, 44 participants, showed a non-statistically sig-
nificant reduction in dichotomous reincarceration, outcomes (RR
1.10, 95%CI 0.37 to 3.26) and continuous outcomes (MD -0.50,
95% CI -8.04 to 7.04) see Analysis 5.2; Analysis 5.3.
Does setting of intervention (community,
prison/secure establishment) affect outcomes of
pharmacological interventions?
All the studies comparing methadone versus non-pharmacological
intervention were conducted in a secure setting; the only study
comparing buprenorphine with non-pharmacological interven-
tion was conducted in the community, as well as the two stud-
ies comparing naltrexone with non-pharmacological treatment. In
the other comparison only one study was included for each, so it
was not possible to perform a subgroup analysis for setting of the
intervention.
Cost and cost-effectiveness
The Magura study noted differences in the costs of administer-
ing buprenorphine and methadone, but were not sufficient for us
to conduct a full cost effectiveness appraisal (Magura 2009). The
investigators estimated that about ten times as many inmates can
be served with methadone as with buprenorphine with the same
staff resources. This cost implication is also endorsed in the com-
munity, where physicians have difficulty in obtaining reimburse-
ment for buprenorphine treatment for released inmates, making
the continued use of buprenorphine problematic after release.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Antagonost(Naltrexone) compared to no pharmacological for drug-using offenders
Patient or population: patients with drug-using offenders
Settings: criminal justice
Intervention: Antagonost(Naltrexone)
Comparison: no pharmacological
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No pharmacological Antagonost(Naltrexone)
Criminal activity di-
chotomous - Reincarcer-
ation
official records
Follow-up: 6 months
Study population RR 0.4
(0.21 to 0.74)
114
(2 studies)
⊕⊕⊕©
moderate1
39 per 100 16 per 100
(8 to 29)
Moderate
44 per 100 17 per 100
(9 to 32)
drug use (objective)
urine screen
Follow-up: 30 days prior
to 6 months
Study population RR 0.69
(0.28 to 1.7)
63
(1 study)
⊕⊕©©
low 2,3
28 per 100 19 per 100
(8 to 48)
Moderate
28 per 100 19 per 100
(8 to 48)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Across the two studies 9 of the 18 risk of bias items were rated as unclear
2 5 of the 9 risk of bias items was rated as unclear
3 only 1 study with 63 participants
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D I S C U S S I O N
Summary of main results
This systematic review provides evidence from 14 trials producing
several meta-analyses. Studies could not be combined all together
because the comparisons were too different. Only subgroup anal-
ysis for type of pharmacological treatment was done. Findings of
the effects of individual interventions on drug use and criminal
activity show mixed results. When compared to non-pharmaco-
logical, we found low quality evidence that agonist treatments are
not effective in reducing drug use or criminal activity. We found
low quality of evidence that antagonist treatment was not effective
in reducing drug use but we found moderate quality of evidence
that they significantly reduced criminal activity. When comparing
the drugs to one another we found no significant differences be-
tween the drug comparisons (methadone versus buprenorphine,
diamorphine and naltrexone) on any of the outcome measures
suggesting that no one pharmacological drug is more effective
than another. Two studies provided some cost comparisons, but
data were not sufficient to generate a cost-effectiveness analysis.
In conclusion, we found that pharmacological interventions do
reduce subsequent drug use and (to a lesser extent) criminal activ-
ity. Additionally, we found individual differences and variation on
different outcome measures when pharmacological interventions
were compared to a non-pharmacological treatment but no sig-
nificant differences when compared to another pharmacological
treatment.
Buprenorphine
The Cropsey study specifically evaluated buprenorphine for opi-
oid-dependent women with HIV risk and found that buprenor-
phine given to participants in prison (followed by its use upon re-
lease into the community) was beneficial in preventing or delaying
relapse to opioid use (Cropsey 2011). The findings of this study
add to the growing body of evidence (which primarily includes
men) suggesting that outcomes with buprenorphine are compara-
ble with what others have found with both methadone and meth-
adone maintenance (Lobmaier 2010). The findings however were
not sustained post treatment, and most women had relapsed to
active opioid treatment at the three-month follow-up point. Fu-
ture studies on the use of buprenorphine in women should eval-
uate its impact on long-term effects with the goal of assessing its
effect on opioid abstinence and prevention of associated crimi-
nal activity (Cropsey 2011). Overall, the dosage of buprenorphine
varied between studies; in one study, instances of 30 mg rising
to 130 mg were reported (Lobmaier 2010). A meta-analysis of
buprenorphine dose and treatment outcome found that a higher
dosage (16 to 32 mg per day) predicted better retention in treat-
ment when compared with a lower dosage (Fareed 2012). Another
Cochrane review (outside the prison environment) indicated that
buprenorphine detoxification and maintenance studies concluded
that completion of withdrawal treatment is possibly more likely
when managed with buprenorphine compared to methadone al-
though the difference was not statistically significant, leading the
authors to conclude that more research is needed to evaluate the
possible differences between the two medications (Gowing 2009).
The Wright 2011 study in this review suggests that there is equal
clinical effectiveness between buprenorphine and methadone in
maintaining abstinence at eight days post detoxification in prison.
Asmany prisoners are eventually released back into the community
the authors note that GPs need to be aware of the few trials which
compare twoof themost commondetoxification agents in theUK.
The research currently supports the use of either buprenorphine
or methadone within a detoxification setting (Wright 2011).
Methadone
Two studies showed a decrease in self-report methadone treatment
upon release into the community (Dole 1969;Magura 2009). The
Dole study, albeit small, found that 3 of 12 prisoners who started
using methadone before release were convicted of new crimes dur-
ing an 11.5-month follow-up compared with 15 of 16 prison-
ers randomly assigned to a control condition (Dole 1969); and
a larger, more recent study found that Rikers Island MMT pro-
gramme in New York significantly facilitated entry and retention
at six months in post release programmes (Magura 2009). In con-
trast, another study reported on opioid agonist maintenance by ex-
amining levo-alpha-acetylmethadol (LAAM) before prison release
and found no significant differences with regard to subsequent
arrest of participants who received LAAM and a control group
at nine months post-release (Kinlock 2005). Subsequent Kinlock
studies involving evaluations of counselling only and counselling
with transfer in comparison with counselling and methadone sup-
port the findings of Dole 1969 and Dolan 2003 suggesting that
methadone programmes can provide effective opioid agonist ther-
apy for prisoners with a history of heroin addiction but not arrest
at 12 month post prison release (Kinlock 2007). Taken together,
the findings also suggest that increased criminal activity and over-
dose death are disproportionately likely to occur within onemonth
of release from incarceration. The authors conclude that making
connections with drug treatment services at release from prison is
likely to help sustain treatment for opiod addictions; such find-
ings are supported by other studies which found that offering pre-
release MMT and payment assistance was significantly associated
with increased enrolment in post-release MMT and reduce time
to enter community-based MMT (e.g. Binswanger 2007). Addi-
tionally, in support of methadone treatment, the World Health
Organisation has listed methadone as an essential medication and
has strongly recommended that treatment should be made avail-
able in prison and supported subsequently within the community
to significantly reduce the likelihood of adverse health and crim-
inogenic consequences (Hergert 2005).
Dosage of methadone treatment varied across studies. For exam-
ple, Magura 2009 reported problems with the use of suboptimal
doses of methadone when higher doses were available. Investiga-
tors argue that higher doses appear to reflect participant preference
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because most did not intend to continue treatment after release.
The Dolan study reported moderate doses of methadone (61 mg)
and noted that outcomes might have improved if higher doses had
been given (Dolan 2003). Significantly lower doses of methadone
were noted in the Dole study, in which 10 mg of methadone per
day was increased to a dosage of 35 mg per day (Dole 1969). Par-
ticipants in the Kinlock 2005 study were medicated three times
per week, starting at 10 mg and increasing by 5 mg every third
medication day during incarceration to a target dose of 50 mg.
Evidence from the Amato 2005 review suggests that low dosages
of methadone maintenance lead to compromise in the effective-
ness of treatment and that recommendations for dosage should
be monitored at around 60 mg. Additional systematic review ev-
idence considering the use of methadone and a tapered dose for
the management of opioid withdrawal shows a wide range of pro-
grammes with differing outcome measures, making the applica-
tion of meta-analysis difficult (Amato 2013). The authors con-
clude that slow tapering with temporary substitution of long-act-
ing opioids can reduce withdrawal severity; however, most partic-
ipants still relapsed to heroin use (Amato 2013).
Naltrexone
For evaluation of naltrexone, two studies (one pilot: Cornish
1997) and Coviello 2010, a subsequent larger replication trial,
show that use of a larger sample size consisting of a diverse group of
offenders resulted in no differences in criminal behaviour between
naltrexone and treatment-as-usual groups. The authors note that
one of the major differences between the two studies remains the
extent and quality of supervision provided by parole officers. The
authors suggest that for treatment to be successful, use of oral
naltrexone by probationers and parolees requires more supervision
than is typically available within the criminal justice system. Study
authors reported instances of 35mg of naltrexone rising to 300 mg
(Coviello 2010). Other research evidence related to naltrexone use
andmortality rates highlights possible concerns about the high risk
of death after treatment. Gibson 2007 compared mortality rates
associated with naltrexone and methadone by using retrospective
data analysis of coronial participants between 2000 and 2003.
Findings show that participants receivingnaltrexonewere up to7.4
times more likely to die after receiving treatment when compared
with those using methadone over the same time period. Although
this study was not conducted in a population of prisoners, it is
likely that such risks are comparable; therefore generalised use of
naltrexone and associated subsequent supervision of those taking
naltrexone in its oral form require careful consideration.
Overall completeness and applicability of
evidence
Overall, the findings of this review suggest that pharmacological
interventions have an impact on reducing self-report drug use. In-
dividual pharmacological drugs had differing effects, particularly
in relation to subsequent drug use. Promising results highlight the
use of methadone or buprenorphine (although this was only one
study) within a prison environment but may be limited to shorter-
term outcomes when prisoners are released into the community.
For naltrexone, the evidence is sparse and presents problems asso-
ciated with different mechanisms of drug administration (e.g. oral
versus implants). We can say little about the cost and cost-effec-
tiveness of these studies. One study reported some descriptive cost
information, but the information was insufficient to generate a
cost analysis (Magura 2009). In conclusion, high-quality research
is required to evaluate the processes involved in the engagement
of offenders mandated to substance abuse programmes to enable
us to understand better why one programme works and another
does not.
Quality of the evidence
A number of limitations within each of the studies are highlighted
by the authors. High dropout rates were noted in the methadone
group after prison release in the Lobmaier study and appear to
be more difficult to maintain in offender populations (Lobmaier
2010). Major limitations of the Coviello 2010 study included low
treatment retention and low six-month follow-up rates. Most of-
fenders did not return for the follow-up evaluation because they
could not be located (63%). Only two-thirds of treated partici-
pants remained in treatment in the Dolan study (Dolan 2003).
As a consequence, the study does not provide conclusive evidence
regarding the efficacy of oral naltrexone in this offender sample.
Attrition was also a problem in Kinlock 2005; this was due in
part to the fact that individuals were being transferred to other
prisons or were having their sentences extended because of pre-
existing charges (Kinlock 2005). Similiar problems of segregation
and impact of sentence releases affected the sample size in the
Bayanzadeh 2004 and Wright 2011 studies whereby transfer to
other prison establishments with little prior warning made follow-
up data difficult to collect. Such attrition within studies threat-
ens the comparability of experimental and control groups, thereby
ensuring that any conclusions should be taken with considerable
caution. In particular, the Bayanzadeh 2004 study noted some of
the practical difficulties associated with contamination between
experimental and control groups, given that the ideal would be
to keep the groups apart. In contrast the pilot study by Brown
2013 produced a study retention rate of 80%; the authors note
that this may be due to the coercive nature of participation in
jail diversion programs in which successful completion may result
in the dismissal or reduction of criminal charges. Although this
finding is represented by only one study it suggests the possibil-
ity that completion of drug treatment programs might fare best
when an incentive which effects sentence or charge outcome can
be sustained.
Sample sizes were considered modest in a number of studies, with
attrition presenting difficulties in interpretation of study findings.
For example, 30%attrition at follow-upproducing possible threats
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to the internal validity of the study design in Magura 2009 and
similar small sample sizes in the Lobmaier trial may have been too
small to reveal any differences between the two treatment con-
ditions (Lobmaier 2010). The Cropsey 2011 study identified a
sample of 36 women and randomly allocated 15 to the interven-
tion and 12 to the placebo group. Investigators note that although
the potency of buprenorphine for control of opioid use is clearly
demonstrated, a larger sample size may be needed to detect sig-
nificant differences between groups on other variables of interest.
Larger trials are therefore required to assess the possible advan-
tages of one treatment over the other. Additionally, the study was
limited to three months of treatment, and further studies should
explore the provision of buprenorphine for longer periods of time
to prolong opioid abstinence and prevent associated criminal ac-
tivity. Similiar short follow-up periods were noted in other trials,
including Dolan 2003.
Potential biases in the review process
Despite limitations associated with the literature, two limitations
in review methodology were achieved. Specifically, the original
review included an additional five fee paying databases and one
search using DrugScope. In this current review resources did not
allow such extensive searching. Whislt the electronic databases
searches have been updated to April 2014. the web site search has
been updated to November 2011. As a result some literature may
have been missed from this current review
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When compared to non-pharmacological treatments, agonist
treatments did not seem effective in reducing drug use or criminal
activity Antagonist treatment was not effective in reducing drug
use but significantly reduced criminal activity. When comparing
the drugs to one another we found no significant differences be-
tween the drug comparisons (methadone versus buprenorphine,
diamorphine and naltrexone) on any of the outcome measures.
Caution should be taken when interpreting these findings, as the
conclusions are based on a small number of trials, and generali-
sation of these study findings should be limited mainly to male
adult offenders. Additionally, many studies were rated at high risk
of bias because trial information was inadequately described.
Implications for research
Several research implications can be identified from this review.
1. Generally, better quality research is required to evaluate the
effectiveness of interventions with extended long-term effects of
aftercare following release into the community.
2. Buprenorphine research in the prison environment requires
evidence of the long-term impact and larger studies, currently an
equivalence of buprenorphine and methadone exists.
3. Evidence for naltrexone is less convincing. Trials evaluating
differences between oral and implantation naltrexone and
associated supervision requirements under the criminal justice
system are required.
4. Only one court diversion study was identified: exploration
of some court diversionary schemes using different
pharmacological interventions would be useful.
5. Future clinical trials should collect information from all
sectors of the criminal justice system. This would enhance the
heterogeneous nature of the included studies and would facilitate
generalisation of study findings.
6. Evidence of comparable mortality rates in prisoners using
pharmacological interventions (particularly after release) needs to
be explored to assess the long-term outcomes of such treatments.
7. The link between dosage, treatment retention and
subsequent criminal activity should be examined across all three
pharmacological treatment options. Evidence from other trial
data suggests that dose has important implications for retention
in treatment; in future studies, this should be considered
alongside criminal activity outcomes.
8. Cost and cost-effectiveness information should be
standardized within trial evaluations; this will help policymakers
to decide upon health versus criminal justice costs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bayanzadeh 2004
Methods Allocation: random assignment
Randomisation method: high risk based on even and odd rows
Similar on drug use: yes
Similar on criminal activity: unknown
Blinding methodology: high-risk participants not blind
Loss to follow-up: inadequate information with some attrition in the control group/high
risk
Participants 120 male participants
100% male
Age range: 20 to 70 years
Mean age: 35.7 years (SD 8.86)
Participants had to have a history of opioid use for longer than one year, had to be
dependent upon drugs and had to have a sentence length greater than 6 months. In
addition, non-death penalty inmates were excluded, and individuals had to be willing to
engage in services
Interventions Intervention group:
The intervention group received methadone treatment in combination with CBT and
widely focused on coping and problem-solving skills. n = 60. The CBT training offered
analysis on the role and thoughts on drug abuse, identification of high-risk situations,
relapse prevention resilience skills, family participation in treatment and motivational
interviewing. Family education was arranged to coincide with weekly visiting hours and
the harm reduction education was delivered once a week
Comparison group:
The comparison group received non-methadone drugs plus standard psychiatric services
and therapeutic medications. An option for treatment using clonidine and psychoactive
drugs was provided as part of this treatment alternative n = 60
Outcomes Drug use: yes/no
Frequency of drug injections (percentage)
Syringe sharing
Morphine urine analysis
All outcomes at six months
Notes After random allocation, 20 participants who were allocated to the control group opted
out of the research. This group of inmates were subsequently replaced by individuals
from the general inmate population
No conflict of interest was reported.
Risk of bias
Bias Authors’ judgement Support for judgement
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Bayanzadeh 2004 (Continued)
Random sequence generation (selection
bias)
High risk Participants were categorised into one of
four lists based on their previous history
of drug abuse. The random allocation was
then chosen, using even and odd row num-
bers from each list
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information reported
Incomplete outcome data (attrition bias)
All outcomes
High risk After random allocation, 20 participants
from the control group opted out of the
research. At the end of the study attrition
was high in both groups: for the interven-
tion group n = 38 out of the original 60
allocated and for the control group n = 31
out of the original 60 allocated
Selective reporting (reporting bias) Unclear risk Not clearly reported but problems with the
research design are highlighted
Other bias High risk The authors note a number of operational
difficulties, especially in relation to con-
tamination across prison wings and the two
intervention groups
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Brown 2013
Methods Allocation: random assignment
Randomisation method: not reported
Similar on drug use: reported that there was no significant between-group difference in
any demographic variable. Variable and data not presented
Similar on criminal activity: as above
Blinding methodology: unclear risk, not reported
Loss to follow-up: high risk, study retention rate reported as 80%, but figure indicates
80% at week 24, 33% at week 52 and 26% at follow-up
Participants 15 adults enrolled in either a drug treatment court (DTC) or Treatment Alternative
Program (TAP). Participants were referred by the Clinical Assessment Unit at theMental
Health Centre of Dane County, where all potential jail diversion program participants
receive initial clinical evaluation
Average age: 27.5 years
53.3 % male
80.0 % white
% drug users, not reported
% alcohol, not reported
% psychiatric history, not reported
Eligibility criteria: inclusion criteria were diagnosis of opioid dependence (via Mini
International Neuropsychiatric Interview (MINI)), opioid positive urine drug screen,
negative screening urine pregnancy test, and willingness to use appropriate birth control
methods throughout the study. Exclusion criteria (via MINI and initial medical history
and physical exam) were current alcohol or sedative dependence, pregnancy, women
whowere breastfeeding, complex psychiatric comorbidity, complexmedical comorbidity,
or pharmacotherapy with an agent contraindicated in combination with suboxone or
methadone, according to drug labelling
Interventions Interventions:
(I) specialist treatment facility plus suboxone (buprenorphine and naloxone)
or (ii) specialist treatment facility plus methadone, n = 9
Control:
(C) primary care plus suboxone (buprenorphine and naloxone), n = 6
Participation lasted 13.5 months, including a 12-month treatment period and a one-
time follow-up 6 weeks post-treatment
Outcomes Primary outcomes included on-going drug usemeasured by timeline follow-backmethod
(TLFB is a reliable, calendar-based technique for retrospectively assessing the frequency
and patterns of daily drug use) and use of the Addiction Severity Index (self report)
Lite, HIV risk behaviours (RAB - Risk Assessment Battery short version), and health
services utilization. TLFB was administered at baseline, bi-weekly for the first 6 months,
and monthly thereafter. All other measures were assessed at baseline, month 6, month
12, and follow-up
Urine drug screens were collected as a part of routine management in DTC and TAP
Notes The project described was supported by the Clinical and Translational Science Award
(CTSA) program, previously through the National Center for Research Resources
(NCRR - now the National Centre for Advancing Translational Sciences, NCATS) grant
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Brown 2013 (Continued)
1UL1RR025011, and grant 9U54TR000021. Funding was also provided by the Vilas
Foundation
The authors report no conflicts of interest.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random allocation noted no further infor-
mation.
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk Small sample size (reported as a “pilot
study”) with 80% completing the 24-week
assessment, 33% completing week 52 and
26% at follow-up
Selective reporting (reporting bias) High risk Protocol reported as being available. How-
ever, on-going drug use (frequency and pat-
terns of daily drug use), health services uti-
lization and urine tests are reported as being
assessed, but no outcome data are reported
Other bias High risk The authors report: “The higher baseline
HIV risk in the specialist study condition,
and, hence, greater potential for risk re-
duction, may have affected this result. In
other words, the relatively low prevalence
of global HIV risk behaviours in the pri-
mary care group may have contributed to a
‘floor effect’ or greater difficulty achieving
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Brown 2013 (Continued)
improvement on this factor.”
“Additionally, urine drug testing was not
collected randomly DTC and TAP where
severity of use affects frequency of testing.
Hence, urine drug test results are likely to
present a biased picture and be difficult to
interpret in aggregate in this community-
based setting.”
Cornish 1997
Methods Allocation: random assignment, 2:1 ratio (naltrexone:control)
Randomisation method: unclear
Similar on drug use: yes
Similar on criminal activity: unknown
Blinding methodology: high risk
Loss to follow-up: unclear risk; some loss to follow-up; volunteer participants
Participants 51 adults randomized, 68 indicated initial interest, of these 2 failed the naltrexone
challenge and 15 did not return for completion of screening and enrollment
Average age: 39 years
90% male
24% white
62% African American
14% Latino
Interventions Community-based naltrexone programme and routine parole/probation (n = 34) vs
routine parole/probation (n = 17)
(I) Nalrexone programe: When a 0.8 naltrexone challenge was negative, the participant
received 25 mg oral dose of naltrexone, if no signs of opioid withdrawal after 1 hour, this
was followed by 25 mg daily for two days and 50 mg daily for the following three days.
Aproximately 1 week after initiation participants were stabilized on naltrexone regimen
of 100 mg on Tuesdays and 150 mg on Fridays. In addition, research staff obtained
observed urine specimens and breathalyzer readings weekly (results of these were not
shared with probation staff )
(C) Routine parole/probation: Participants were required to attend three orientation and
counseling sessions per week for the first 2 weeks of the study
Both groups received weekly parole/probation officer contact for the first 6 months and
medication visits occured twice weekly. At 6-month follow up participants were give a
$25 incentive payment and at 9, 12, 15 and 18 month follow up participants were given
$25 for keeping scheduled appointments
Outcomes Reincarceration for technical violation (official records) during the past 6 months at 6
months’ follow-up
Mean percentage for opioid positive urine specimens per group
Notes Work supported by NIDA Grant DA05186.
No declarations of interest are noted by the authors
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Cornish 1997 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Individuals were assigned at a ratio of 2:1
to naltrexone vs control
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
subjective outcomes
High risk Study description suggests that participants
were not blind: see p.531
Blinding of participants and personnel
(performance bias)
objective outcomes
High risk Study description suggests that participants
were not blind: see p.531
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Blinding of urine samples were not shared
with probation staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk All allocated participants were reported in
the analysis. Retention rates appeared to be
similar; appears to be an ITT analysis
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Unclear risk Groups similar at baseline, but potential for
volunteer bias
Coviello 2010
Methods Allocation: random
Randomisation method: unknown/unclear
Similar on drug use: significant difference in heroin use. Otherwise similar
Similar on criminal activity: yes
Blinding methodology: high risk
Loss to follow-up: inadequate/high risk
Participants 111 adults
Age range: 18 to 55 years; average age: 34 years
82% male
47% Caucasian
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Coviello 2010 (Continued)
100% drug users
Alcohol use not reported but participants excluded if severe alcohol dependence
Psychiatric history not reported
Eligibility criteria: consented, age 18 to 55 years, opioid dependence, otherwise good
health, probation or parole for 6 months, 3 days opioid free
Interventions Community pharmacological intervention vs treatment as usual
(I) Oral naltrexone plus psychosocial treatment (n = 56) vs (C) psychosocial treatment
only (n = 55)
The (I) group was started on directly observed administration of naltrexone, increasing
in dose from 25 mg to 300 mg and was also given psychosocial treatment. The (C) group
was given a treatment regimen consisting of group therapy, individual therapy and case
management, all of which the (I) group also received
Outcomes Criminal activity (self-reported) and criminal record data at 6 months
Illicit drug use (self-reported) during the 30 days before the interview at 6 months
% positive urine drug screen for opioids
% positive urine drug screen for cocaine
Notes The study was supported by grant R01-DA-012268 from theNational Institute onDrug
Abuse, Bethesda, MD (Dr. Cornish)
Declaration of Interest In the past 3 years, Dr. O’Brien has served as a consultant on one
occasion to Alkermes, a company that makes a version of depot naltrexone. He is also
conducting an NIH-funded study of this medication in opioid addiction. The authors
report no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method unclear. Note that
randomisation was balanced by using six
variables
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
subjective outcomes
High risk page 4 ’we did not use a placebo for partic-
ipants’. The treatment as usual group were
not blinded
Blinding of participants and personnel
(performance bias)
objective outcomes
High risk page 4 ’we did not use a placebo for partic-
ipants’. The treatment as usual group were
not blinded
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information provided
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Coviello 2010 (Continued)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk A large amount of attrition was noted in
the first week, and only one-third of par-
ticipants remained at 6-month follow-up
Selective reporting (reporting bias) Unclear risk No information provided
Other bias High risk Blinding and attrition concerns through-
out the study
Cropsey 2011
Methods Allocation: randomassignment, randomnumber table first 9 people put on intervention
Randomisation method: sealed envelopes opened at the end of treatment
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: double-blinded. Placebo was used and was not known to evalu-
ators or dispensers during treatment
Loss to follow-up: partial a few individuals not included in the final analysis
Participants 36 adults
Mean age: 31.8 years (SD 8.4)
100% female
89% white
100 drug users
Alcohol use: yes percentage not available
54.3% prescribed medication for mental illness
Eligibility criteria: adult women, opioid dependent, interest in treatment for opioid
dependence, no contraindications for buprenorphine, due for release from residential
treatment within the month, returning to the community, release to correct area
Interventions Community-based pharmacological intervention vs placebo
(I) buprenorphine (n = 24) vs (C) placebo (n = 12)
(I) group was started on 2 mg of buprenorphine, increased to target dose of 8 mg
at discharge. Only 37.2% reached target dose at discharge. (Doses were lower than
standard induction, as participants had been in a controlled environment for some time
without access to opiates.) Doses were titrated up to a maximum of 32 mg per day in
the community, as clinically indicated. Participants were assessed weekly for side effects,
were given drug testing and were counselled by the study physician if using drugs. The
treatment course was 12 weeks
The (C) group was given a placebo on the same regimen as the (I) group
Outcomes % injection drug use and % urine opiates at end of treatment and at 3 months’ follow-
up
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Cropsey 2011 (Continued)
Notes This project was supported by funding from NIDA R21DA019838
and product support from Reckitt Benckiser Pharmaceuticals Inc
The authors have no declarations of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk First 9 participants deliberately allocated to
intervention for practical reasons; use of a
random number table
Allocation concealment (selection bias) Low risk Use of sealed envelopes
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk This trial began as an open label trial then
became a double blind trial of participants
and providers on all outcomes. Some con-
cerns about contamination issues with the
placebo group but difficult to assess to what
extent the blinding might have been af-
fected
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk This trial began as an open label trial then
became a double blind trial of participants
and providers on all outcomes. Some con-
cerns about contamination issues with the
placebo group but difficult to assess to what
extent the blinding might have been af-
fected
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No evidence to provide information about
whether the assessors were blind
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No evidence to provide information about
whether the assessors were blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A total of 8 individuals were not included
in the final analysis after randomisation
Selective reporting (reporting bias) Unclear risk No information reported
Other bias Low risk Noother concerns within themethodology
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Dolan 2003
Methods Allocation: random allocation
Randomisation method: low risk, cards drawn from sealed envelope
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: high risk, treatment and comparator (methadone or wait list)
would not permit blinding.No statement that the outcome assessment was blind (unclear
risk)
Loss to follow-up: high risk, > 30% in both groups excluded from 4-month follow-up
Participants 382 adults and young offenders
Mean age: 27 years (SD 6)
100% male
Ethnicity: not reported
100% drug-using
Alcohol use: not reported
Psychiatric history: not reported
Eligibility criteria: prisoners with a heroin problem, as confirmed by a detailed interview,
who have at least 4 months remaining on their prison sentence at time of interview
Interventions Secure establishment-based pharmacological intervention versus waiting-list control
(I) methadone maintenance (n = 191) vs waiting-list control (n = 191)
(I) Participants were given 30 mg of methadone each day, increasing by 5 mg every 3
days until 60 mg was achieved; duration in treatment varied. Duration of waiting-list
was 4 months
At 5 months, all participants were offered methadone through the prison-based metha-
done treatment programme. Released subjects who had been treated through the prison
methadone programme were offered the opportunity to transfer to local community
methadone programmes
Outcomes Dolan 2003: primary study
Heroin use (hair analysis) and self-reported heroin use during the past 2 months at 2
months’ follow-up
Drug injecting during the past 3 months at 3 months’ follow-up.
Syringe sharing and HIV/HCV seroconversion during the past 4 months at 4 months’
follow-up
Dolan 2005: 4-year follow up
Long-term outcomes at four years including mortality, reincarceration, hepatitis C sero-
conversion and HIV seroconversion
Notes Funding was provided by the Commonwealth Department of Health and Family Ser-
vices, Glaxo Wellcome, the NSW Department of Health and the National Drug and
Alcohol Research Centre, UNSW
The authors have no declarations of interest
Risk of bias
Bias Authors’ judgement Support for judgement
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Dolan 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Central randomisation by phone
Allocation concealment (selection bias) Low risk Allocation held by researcher not involved
in recruiting or interviewing participants.
Trial nurses had no access to lists
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk Treatment and comparator (methadone or
wait list) would not permit blinding
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk Treatment and comparator (methadone or
wait list) would not permit blinding
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition > 30% in both groups and ITT
not undertaken. At follow-up, 129 (68%)
treated and 124 (65%) control subjects
who had been in continuous custody were
reinterviewed. 29 treated and 33 control
subjects had been released from prison and
were excluded. No data on other partici-
pants not accounted for at follow-up
Selective reporting (reporting bias) Low risk All outcomes in objectives were reported in
results
Other bias Low risk Baseline characteristics largely similar (p
61)
Some control participants received Tx,
some Tx not given; methadone tested by
subgroup analysis
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Dole 1969
Methods Allocation: random assignment
Randomisation method: lottery method
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: unclear and not reported
Loss to follow-up: adequate/low risk
Participants 32 males
Heroin addicts 5 years or longer
5 or more previous convictions
15 European, 10 negro, 7 Puerto Rican
With a population of heroin-dependent prerelease prisoners
Interventions Methadone (n = 12) vs waiting-list control (n = 16).
Methadone was prescribed on admission to a hospital unit where individuals were given
10 mg per day, gradually increasing to a dose of 35 mg
Outcomes Heroin use
Reincarceration
Treatment retention
Employment
At 7 to 10 months, 50 weeks
Notes Participants were chosen by a lottery based on release dates between January 1 and April
30 1968
Supported by grants from theHealth ResearchCouncil and theNewYork StateNarcotics
Addiction Control Commission
No declarations of interest by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by lottery, no further details of
the study method provided
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information provided
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Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data on key outcomes
Selective reporting (reporting bias) Unclear risk Intention-to-treat analysis not reported
Other bias Unclear risk Representativeness of the small samplewith
no urine analysis in follow-up of controls
Howells 2002
Methods Allocation: random assignment
Randomisation method: method not reported
Similar on drug use: yes
Similar on criminal activity: not reported
Blinding methodology: low risk, double-blind with blinded outcome assessment
Loss to follow-up: high risk, 21 participants (27.63%) (13/32 lofexidine, 8/36 metha-
done) were withdrawn from the trial prematurely
Participants 80 adult participants was planned, in the time available for the trial, 76 patients met eli-
gibility criteria and gave their consent to participate. Of these, two patients immediately
elected to withdraw from the trial. In error, six patients were entered into the trial for a
second detoxification after completing the trial on the first occasion and then receiving
a separate prison sentence following release. Four of these patients were randomised to
the other drug on second entry
Average age: The ages of the lofexidine and methadone groups were similar (29.8 years
[range 22 to 43] and 30.5 years [range 22 to 49] respectively, P = 0.65)
100% male
% white not reported
Use of heroin was reported by 97.1% (n = 66) of the participants during the previous
month and 89.7% reported heroin to be their main problem substance
% alcohol not reported
% psychiatric history not reported. Major psychiatric illness was an exclusion criterion
Eligibility criteria: Consenting patients were required to be under 55 years old and
to meet DSM-IV criteria for opioid dependence and induced withdrawal (American
Psychiatric Association, 1994). Participant exclusion criteria were concurrent serious
major psychiatric illness (schizophrenia, psychotic depression) or serious physical illness
thatwould prevent participation in the trial.Opioid usewas confirmedby urine screening
for the presence of urinary opioid metabolites
Interventions Intervention:
(I) Placebo syrup as a green aqueous solution and lofexidine peach-coloured tablets twice
daily for 10 days (n = 32)
Control:
(C) Methadone as a green liquid (1 mg/ml), and placebo peach-coloured tablets, twice
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daily for 10 days
Following the manufacturer’s datasheet the Lofexidine (Britlofex) regimen consisted of
an initial daily dose of 0.6 mg (with 0.2 mg administered in the morning and 0.4 mg at
night) increasing by 0.4 mg daily (two tablets) until day 4. At this point the dose was
maintained at 2 mg daily (five tablets twice a day) for 3 days. Over the next 3 days the
dose was tapered by 0.4 mg per day. The gradual dose reduction was designed to prevent
any possible rebound hypertension (n = 36)
Outcomes The primary outcome measure was withdrawal symptom severity measured using two
withdrawal scales: the 20-item Withdrawal Problems Scale (WPS), and the eight item
ShortOpiateWithdrawal Scale (SOWS).The participants self-completed thewithdrawal
scales each morning. Given limited item overlap between the two scales, a composite 28-
item total withdrawal symptoms scale was computed to facilitate presentation of results.
To analyse the total daily scores for each scale, the following global indices were derived:
the highest daily score observed and the time of the occurrence, the lowest daily score
observed and the time of the occurrence, the total score summed over all 10 days of the
trial
Secondary outcome measures were rates and timing of withdrawal from the detoxifica-
tion programme so that the relationship between failure to complete detoxification and
severity of withdrawal symptoms could be measured
The Severity of Dependency Scale (SDS) was also used to assess the severity of psycho-
logical aspects of drug dependence
Notes Britannia Pharmaceuticals provided the medication.
No declarations of interest statement included in the trial report
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The authors report “The pharmacist who
made up the medication used a simple ran-
domisation procedure to allocate each par-
ticipant to one arm of the trial” but no fur-
ther description is reported
Allocation concealment (selection bias) Unclear risk The authors report “The independent
pharmacy team at the prison oversaw the
randomisation and blinding procedure…”,
but no statement that allocation was con-
cealed
Blinding of participants and personnel
(performance bias)
subjective outcomes
Low risk “…both the patient and health centre clin-
icians were blind to the assigned treatment
group”
Blinding of participants and personnel
(performance bias)
objective outcomes
Low risk The authors report “The independent
pharmacy team at the prison oversaw the
randomisation and blinding procedure…”,
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but no statement that allocation was con-
cealed
Blinding of outcome assessment (detection
bias)
subjective outcomes
Low risk “…blinding was maintained during treat-
ment of the patients and during data entry
and analysis”
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk “…blinding was maintained during treat-
ment of the patients and during data entry
and analysis”
Incomplete outcome data (attrition bias)
All outcomes
High risk Twenty-one participants (27.63%) (13/32
lofexidine, 8/36 methadone) were with-
drawn from the trial prematurely. ITT not
used, data analysed per-protocol
Selective reporting (reporting bias) Low risk The authors indicate that there was a pro-
tocol for the study (“Patient safety elements
in the protocol were as follows:”) and pri-
mary and secondary outcomes are clearly
defined. Outcomedata for the primary and
secondary outcomes are reported
Other bias High risk The authors report “Four of these patients
were randomised to the other drug on sec-
ond entry. As a check on results, we re-
peated the analyses with the exclusion of
these six cases. Whilst both the direction
andmagnitude of the resultswere unaltered
we removed these cases from the dataset
and the remaining results relate to the re-
duced sample of 68 patients.”
Kinlock 2005
Methods Allocation: random assignment
Randomisation method: unclear
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: unknown
Loss to follow-up: inadequate/high risk
Participants 126 adult males
Age: 35.7 years (SD 6.8)
100% male
14% white
100% drug users
Alcohol use: not reported
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Eligibility criteria: 3 months before anticipated release from prison, history of heroin
dependence meeting DSM-IV criteria
Interventions (I) Prison/secure establishment-based levo-alpha-acetyl methanol + transfer to metha-
done maintenance after release (n = 20) vs (C) untreated controls (31) and withdrew
before treatment (N = 13)
(I) Participants medicated 3 times per week starting at 10 mg and increasing by 5 mg
every third medication day during incarceration to a target dose of 50 mg. At release
participants were advised to report to the program’s communirty ased maintenance
facility for continuing care
(C) Received community treatment referral information only.
Outcomes Heroin use during 9-month follow-up (self-report), arrests during 9-month follow-up
(official records) and reincarceration during 9-month follow-up (official records), fre-
quency of illegal activity, admission to drug use and average weekly income obtained
from illegal activities, mean number of crime days
Notes No funding information provided
No declaration of interest by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported other than stated
’random’
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information reported
Incomplete outcome data (attrition bias)
All outcomes
High risk A considerable number of experimental
participants declined medication after ini-
tial consent and randomisation to the ex-
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perimental condition (see pp. 437 and
499). High attrition from the experimen-
tal group after random assignment and be-
fore treatment initiation required revision
of the original two-group study design for
purposes of data analyses
Selective reporting (reporting bias) High risk Table 4, p. 446, indicates only selected out-
comes. No ITT conducted
Other bias High risk Experimental and control groups could not
be considered comparable (p. 449); there-
fore, the number of variables was restricted.
Study groups were revised after attrition in
treatment group. Groups were considered
not to be comparable, and the number of
variables assessedwas restricted. Urine sam-
ples and treatment records available on ex-
perimental group only
Kinlock 2007
Methods Allocation: random assignment
Randomisation method: block randomised
Similar on drug use: unknown
Similar on criminal activity: unknown
Blinding methodology: high risk
Loss to follow-up: adequate
Participants 211 adult males
Age: group (a) 40.9 years (SD 7.6), (b) 40.3 years (7.0), (c) 39.8 years (7.0)
100% male
% white: group (a) 31.3%, (b) 19.7%, (c) 20%
100% drug users
Alcohol use not reported
Psychiatric history not reported
Eligibility criteria:
(1) 3 to 6 months before release from prison; (2) meeting Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) criteria of heroin dependence at time of in-
carceration and being physiologically dependent during the year prior to incarceration;
(3) no pending parole hearings and/or unadjudicated charges; (4) having a Baltimore
city address post-release; and (5) suitability for methadone maintenance as determined
by medical evaluation. Inmates were excluded from study participation if they had any
unadjudicated charges and/or pending parole hearings
Interventions (C) Counselling Only: counselling in prison and passive referral to community-based
drug treatment (n = 70)
(I) Counselling + Transfer: counselling in prison and transfer to methadone maintenance
in the community upon release beginning with 5 mg of methadone and increasing by 5
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mg every eighth day to a target minimum dose of 60 mg (n = 70)
(I) Counselling + Methadone: counselling and methadone in prison with transfer to
methadone treatment in the community upon release, begininning with 5 mg dose of
methadone and increasing by 5 mg every eighth day during incarceration to a target dose
of 60 mg. Advised to report to the program’s community-based methadone program
within 10 days of release for continuing care (n = 71)
Outcomes Kinlock 2007: primary study
Urine test for opioids 1 month post-release, urine test for cocaine 1 month post-release,
self-report heroin use 1 month post-release, self-report cocaine use 1 month post-release
Gordon 2008: 6 month follow up study
Urine testing for opioids, cocaine and other illicit drugs 6 months post-release, treatment
record review, Addiction Severity Index (ASI) from baseline and follow up
Wilson 2012: follow up study
Post-release changes over time in the specific HIV risk behaviours in which the par-
ticipants had a prior history of engaging. Participants were assessed at baseline (study
entry in prison), and at 1-, 3-, 6-, and 12-month post-release. The primary outcome
measures at each time period were self-reported participation in risky drug- and sex-risk
behaviours obtained from the Texas Christian University AIDS Risk Assessment (ARA)
Notes Funding for this studywas provided byGrant R01DA16237 from theNational Institute
on Drug Abuse (NIDA)
No declarations of interest reported by the authors.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information reported
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Incomplete outcome data (attrition bias)
All outcomes
High risk Individuals in the counselling only group
did not receive treatment
Selective reporting (reporting bias) Unclear risk No information reported
Other bias High risk Contamination of treatment groups
Lobmaier 2010
Methods Allocation: random
Randomisation method: permuted block protocol
Groups similar on drug use at baseline: yes
Groups similar on criminal activity at baseline: yes
Blinding methodology: not blinded open label
Loss to follow-up: unknown
Participants 46 adults
Mean age: 35.1 years (SD 7)
93% male
Ethnicity: unknown
100% drug users. 86.4% polydrug use
Alcohol use: not reported
Psychiatric history: not reported
Eligibility criteria: inclusion: pre-incarceration heroin dependence, at least 2 months
sentence time remaining. Exclusion: untreated major depression or psychosis, severe
hepatic impairment, already in agonist maintenance treatment, pregnant
Interventions Secure establishment naltrexone intervention vs methadone treatment
(I) Received 20-pellet naltrexone implants around one month before release. Implants
give sustained-release naltrexone over 5 to 6 months (n = 23) vs
(C) Initiated on 30 mg methadone per day at around one month pre-release. Increased
over typical period of three weeks to recommended dose of 80 to 130 mg (n = 21)
Outcomes Mean days per month of criminal activity (self-reported) at 6 months
No. of days in prison (from official records of Norwegian prison) at 6 months
Mean days per month using heroin, benzodiazepines and amphetamines (self-reported)
at 6 months
Notes Funding was provided by the Research Council of Norway
No declarations of interest by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment allocation sequence performed
at an independent centre using a permuted
block protocol
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Allocation concealment (selection bias) Low risk Sequentially numbered, sealed, opaque en-
velopes
Blinding of participants and personnel
(performance bias)
subjective outcomes
High risk p143 “the treatment conditions were not
blind and may have increased risk if perfor-
mance bias”
Blinding of participants and personnel
(performance bias)
objective outcomes
High risk p143 “the treatment conditions were not
blind and may have increased risk if perfor-
mance bias”
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis conducted
Selective reporting (reporting bias) Unclear risk No evidence
Other bias Low risk No other concerns
Lobmann 2007
Methods Allocation: random assignment
Randomisation method: block randomised
Similar on drug use: unknown
Similar on criminal activity: unknown
Blinding methodology: unknown
Loss to follow-up: adequate
Participants 1015 drug-using offenders
Age: 36 years (SD 6.7)
% male not reported
% white not reported
100% drug users
Alcohol use not reported
Eligibility criteria: min age 23 years, ICD-10 opiate addiction, opiate addiction min 5
years, current daily heroin consumption,OTI scale health problems, not received therapy
for addiction during past 6 months
Interventions Community-based: diamorphine treatment (n = 500) vs methadone treatment (n = 515)
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Outcomes 12 months follow up and outcomes.
Drug use and criminal activity (self-report and official records)
Notes Article in German, single reviewer translation completed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation used
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data on all outcomes presented, limited at-
trition noted
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Unclear risk No information provided
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Methods Random allocation: to methadone or buprenorphine allocation initially on a 1:1 ratio
and subsequently periodically based on 7:3
Randomisation method: inadequate, personnel aware of allocation
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: unknown
Loss to follow-up: inadequate, up to 30% lost
Participants 133 male inmates
Age: group (a) 38.4 years (SD 7.9), (b) 40.7 years (9.1)
100% male
25% black, 64% Hispanic
100% drug users
Alcohol use: not reported
Eligibility criteria: inmates who were eligible for the Key Extended Entry Program
(KEEP), 18 to 65 years old, sentenced to 10 to 90 days’ jail time, and expected to reside
locally post-release
Interventions Prison/secure establishment based methadone (n = 56) vs buprenorphine (n = 77)
(C) Methadone: Participants were given liquid methadone dispensed once daily usual
maintenance dose was 30 mg which could be stepped up to a maximum of 70 mg if
clinically indicated and participant agreed
(I) Buprenorphine: The sublingual combination burprenorphine/naloxone tablet was
used for both induction and maintenance, initial dose of 4 mg which could be stepped
up to 8 mg on the first day and could be stepped up to 32 mg on subsequent days.
Participants observed until the tablet had dissolved
Outcomes Arrest (self-report) during the past 12 months at 3-month follow-up for property crime,
drug posession and % reincarcerated. Drug use past 30 days (self-report), mean number
of days heroin use post-release at 3-month follow-up
Notes No funding information provided by the authors
No declarations of interest reported by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number generator used. Alloca-
tion was originally 1:1, but loss in one
group meant that treatment-adaptive ran-
domisation was used at a ratio of 7:3
Allocation concealment (selection bias) High risk Project director was naive to allocation, but
research assistant was not
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No information provided
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Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some attrition occurred before medication
was received by buprenorphine-assigned
participants. 30% of participants could not
be interviewed at follow-up
Selective reporting (reporting bias) Unclear risk No information reported
Other bias High risk Participants at one site receivedmethadone
suboptimal doses (30 mg). The study con-
tained a modest sample size
Wright 2011
Methods Allocation: random allocation
Randomisation method: low risk, generated using Microsoft Excel
Similar on drug use: yes
Similar on criminal activity: not reported
Blinding methodology: high risk, open-label
Loss to follow-up: high risk
Participants 439 eligible adults of whom 133 declined leaving 306 available for randomisation. Sev-
enteen excluded at randomisation
289 adults randomised and allocated
The median age was 30.8 years (interquartile range (IQR), 26.9 to 34.9)
% male, not reported - mixed sample (1 all-female and 2 all-male prisons)
Methadone, 89.9 % white; buprenorphine, 93.6% white
% drug users not reported
% alcohol, not reported
% Psychiatric history, not reported
Eligibility criteria: Inclusion criteria: 21 to 65 years old; using illicit opiates as confirmed
by urine test; expressing a wish to detoxify and remain abstinent; willing to give informed
consent; and remaining in custody for at least 28 days. Exclusion criteria: contraindi-
cations to methadone or buprenorphine; medical conditions requiring emergency ad-
mission to hospital, thus precluding detoxification; currently undergoing detoxification
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from other addictive drugs whereby concurrent opiate detoxification would not be clin-
ically indicated; and previously randomised into the trial
Interventions Sublingual buprenorphine (n = 141) vs Oral methadone (n = 148)
(I) Sublingual buprenorphine: prescribed daily within set dose limits of 8 mg for days 1
to 5, 6 mg for days 6 to 7, 4 mg for days 8 to 10 and subsequently descreasing to a limit
of 0.4 on day 20
(C) Oral methadone (1mg/1ml mixture): prescribed daily within set dose limits of 30
mg for days 1 to 5, 25 mg for days 6 to 7, 22 mg for days 8 to 9, 20 mg for days 10 to
11 and subsequently descreasing to a limit of 2 mg on day 20
Outcomes The primary outcome was abstinence from illicit opiates at 8 days post detoxification,
as indicated by a urine test
Secondary outcomes included abstinence status at 1, 3, and 6months post detoxification,
ascertained via urine test if the participant was still in prison. If the participant had
been released, local community drugs service records were accessed to verify abstinence.
Adverse events were recorded and a researcher was informed immediately of any serious
adverse events, which were then reported to the regulatory authorities. These included
overdose, self-harm, or suicide attempt; inappropriate use of prescribed medication; or
admission as a prison healthcare inpatient
Notes Funded by Department of Health, National Research and Development Programme on
Forensic Mental Health Research Funding Scheme 2004
The authors state that they have no competing interests.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation sequence (with random
block size) was generated using Microsoft
Excel RAND function
Allocation concealment (selection bias) Low risk Sealed, opaque, consecutively numbered
envelopes concealing the name of the allo-
cated intervention were prepared by a re-
searcher who had no contact with partici-
pants
Blinding of participants and personnel
(performance bias)
subjective outcomes
High risk Open label “The prescribing doctor ran-
domised by opening the next envelope and
prescribing the intervention named inside.
Both prisoner and doctor were blind to the
intervention until this point.”
Blinding of participants and personnel
(performance bias)
objective outcomes
High risk Open label “The prescribing doctor ran-
domised by opening the next envelope and
prescribing the intervention named inside.
Both prisoner and doctor were blind to the
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intervention until this point.”
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No statement regarding blinding of in-
dividual who undertook the biochemical
urine tests
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No statement regarding blinding of indi-
vidual who recorded self-report or clinical
notes
Incomplete outcome data (attrition bias)
All outcomes
High risk High levels of attrition. 50% buprenor-
phine and 45%methadone did not provide
urine sample at day 8, 65% and 62% at
1 month, 80% and 85% at 3 months and
86% and 91% at 6 months. ITT under-
taken assuming if no objective or subjective
data available, participants were not absti-
nent
Selective reporting (reporting bias) High risk Adverse events and reasons for withdrawal
stated as being recorded but no outcome
data reported
Other bias Low risk No other concerns
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alemi 2010 Does not concern pharmacological intervention
Alessi 2011 Not original RCT. Data is from previous, older studies.
Andersson 2014 Intervention not aimed at reducing drug use or criminal activity, or both
Anglin 1999 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Awgu 2010 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Azbel 2013 Intervention not aimed at reducing drug use or criminal activity, or both
Baldus 2011 Study protocol only, author has since died.
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Baltieri 2014 Intervention not aimed at reducing drug use or criminal activity, or both
Barnes 2012 Not using a population of drug-using offenders
Berman 2004 The intervention was not aimed at reducing drug use or criminal activity or both in drug-using offenders
Black 2011 Not offender population
Brady 2010 Not RCT
Braithwaite 2005 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Breckenridge 2000 Evaluated a DWI Court for alcoholic offenders, not illicit drug use, not a pharmacological intervention
Britt 1992 a-d Does not concern pharmacological intervention.
Brown 2001 3-arm study in which only 2 arms were randomised - 1 treatment arm and control arm. Results presented as
both treatment arms combined vs control
Burdon 2013 Not a trial.
Carr 2008 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Carroll 2006 Does not concern pharmacological intervention
Carroll 2011 Not offender population
Carroll 2012 Not a pharmacological intervention.
Chandler 2006 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Chaple 2014 No pre- and post-test measures of drug or crime, or both.
Clair 2013 No data presented at pre- and post-test outcomes for crime and drug
Cogswell 2011 Population not offenders.
Cosden 2003 Does not concern pharmacological intervention
Cosden 2005 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Coviello 2012 Not a Randomised Controlled Trial
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Cox 2013 Not an offender population
Cropsey 2013 Not a Randomised Controlled Trial
Cullen 2011 Not a drug program aimed at reducing drug use/criminal activity in drug using offenders
Cusack 2010 Not a drug program aimed at reducing drug use/criminal activity in drug using offenders
D’Amico 2013 Does not present data for pre- and post-test information on drug or crime measures, or both
Dakof 2010 Study population is mothers of offenders, not offenders themselves
Dana 2013 Not an RCT
DeFulio 2013 Not an RCT
Dembo 2000 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods.
The follow-up periods reported for the different groups were not equivalent
Deschenes 1994 Does not concern pharmacological intervention
Di Nitto 2002 The follow-up periods reported for the different groups were not equivalent
Diamond 2006 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Dugan 1998 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Evans 2012 Not an RCT
Forsberg 2011 Does not concern pharmacological intervention
Freudenberg 2010 Does not concern pharmacological intervention
Friedman 2012 Not an RCT
Frost 2013 Not an RCT
Gagnon 2010 Not offender population
Gil 2004 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Gordon 2012 No relevant data; all analysis at baseline; no pre- and post-test information on drug use or criminal activity,
or both
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Gordon 2013 No relevant data; all analysis secondary, not a primary RCT.
Gottfredson 2002 Does not concern pharmacological intervention
Grohman 2002 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Grommon 2013a Not a pharmacological intervention.
Grommon 2013b Not a pharmacological intervention.
Guydish 2011 Does not concern pharmacological intervention
Guydish 2014 Not criminal justice population
Haapanen 2002 Does not concern pharmacological intervention
Haasen 2010 Not offender population
Hanlon 1999 Does not concern pharmacological intervention
Harada 2012 No data on pre- and post-test outcomes for drug or criminal justice, or both
Harrell 2001 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Henderson 2010 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Henggeler 1991 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Henggeler 1999 Does not concern pharmacological intervention
Henggeler 2002 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Henggeler 2006 Does not concern pharmacological intervention
Henggeler 2012 Not a pharmacological intervention.
Hser 2011 Unclear if study looks at offender population
Hser 2013 Not a pharmacological intervention
Inciardi 2004 Some participants were not randomly selected into the treatment groups
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Jain 2011 Paper not available and not clear from abstract if looks at offender population
Johnson 2011 Does not concern pharmacological intervention
Johnson 2012 Does not concern pharmacological intervention
Jones 2013 Not a pharmacological intervention
Jones, 2011 Evaluated a DWI Court for alcoholic offenders, not illicit drug use
Katz 2007 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Kelly 2013 Not a pharmacological intervention.
Kidorf 2013 Not offender population
King 2014 Not offender population
Kinlock 2008 Not a pharmacological intervention.
Kinlock 2009a Conference proceedings only
Kinlock 2009b Not a pharmacological intervention
Kok 2013 Not offender population
Law 2012 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Lee 2012 No pre- and post-test data for outcomes of drug or criminal justice measures, or both
Liddle 2011 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Ling 2013 Not offender population
Lobmann 2009 No pre- and post-outcome measures for drug or crime outcomes, or both
MacDonald 2007 Evaluated a DWI Court for alcoholic offenders, not illicit drug use
Marlowe 2003 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Marlowe 2005 Not a pharmacological intervention
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Marlowe 2007 Participants randomised to receive treatment were not randomised into the different treatment groups but
were identified by level of risk. Not an RCT
Marlowe 2008 Does not concern pharmacological intervention
Marsch 2014 Not offender population
Martin 1993 Does not concern pharmacological intervention
Mbilinyi 2011 Participants not recruited through criminal justice system
McKendrick 2007 The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
McKenzie 2012 Does not concern pharmacological intervention
Messina 2000 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention.
The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Messina 2010 No pharmacological interventions
Milloy 2011 No pre- and post-data for outcomes of crime or drug use, or both
Needels 2005 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Nemes 1998 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention.
The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Nemes 1999 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention.
The study did not report relevant drug or crime outcome measures, or both, at both the pre- and post-
intervention periods
Nielsen 1996 Does not concern pharmacological intervention
Nosyk 2010 Not offender population
Petersilia 1992 Does not concern pharmacological intervention
Petry 2005 Not 100% criminal justice population.
Petry 2011 Not offender population
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Polsky 2010 Not offender population
Prendergast 2003 Does not concern pharmacological intervention
Prendergast 2008 Does not concern pharmacological intervention
Prendergast 2009 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and post-
intervention periods
Prendergast 2011 Does not concern pharmacological intervention
Proctor 2012 No pharmacological interventions
Reimer 2011 Not offender population
Robertson 2006 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Rosengard 2008 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and post-
intervention periods
Rossman 1999 Does not concern pharmacological intervention
Rounsaville 2001 No pre- and post-test data presented on drug use or crime outcomes, or both
Rowan-Szal 2005 Population not offenders.
Rowan-Szal 2009 Not RCT
Rowe 2007 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Sacks 2004 Does not concern pharmacological intervention
Sacks 2008 Does not concern pharmacological intervention
Sacks 2011 Does not concern pharmacological intervention
Sanchez-Hervas 2010 Population not offenders.
Schaeffer 2014 Does not contain a pharmacological intervention
Schmiege 2009 No data for pre- and post-test outcome measures of drug or crime outcomes, or both
Schwartz 2006 Not offender population
Shanahan 2004 This is not a pharmacological intervention
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Sheard 2009 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and post-
intervention periods
Siegal 1999 Not RCT
Sinha 2003 Not a pharmacological intervention.
Smith 2010 Does not concern pharmacological intervention
Solomon 1995 Not an offender population.
Specka 2013 Not an offender population.
Stanger 2009 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Staton-Tindall 2009 No control group; not an RCT.
Stein 2006 No pre- and post-test data for drug or crime outcome measures, or both
Stein 2010 Not offender population
Stein 2011 Does not concern pharmacological intervention
Stevens 1998 The population of the study was not 100% drug-using offenders that were specifically referred by the criminal
justice system to the intervention
Svikis 2011 Not clear if offender population
Taxman 2006 Does not concern pharmacological intervention
Vagenas 2014 No pre- and post-test data on drug or crime outcome measures, or both
Vanderberg 2002 No pre- and post-test outcome data on crime or drug measures, or both
Villagrá Lanza 2013 Does not concern pharmacological intervention
Walters 2014 No data on pre- and post-test information for drug or crime outcome measures, or both
Wang 2010 Participants not in criminal justice system
Webster 2014 No data on pre- and post-test information for drug or crime outcome measures, or both
White 2006 Randomisation broken as 40% of control arm were allowed to receive treatment (acupuncture) outside of
the intervention
Williams 2011 Not RCT
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Winstanley 2011 Not clear if offender population
Witkiewitz 2010 Not clear if offender population
Wolff 2012 No data for pre- and post-test outcomes of drug or crime measures, or both
Zlotnick 2009 Does not concern pharmacological intervention
Characteristics of ongoing studies [ordered by study ID]
Springer 2015
Trial name or title Naltrexone for opioid dependent released HIV+ criminal justice populations
Referred to as NEWHOPE.
Methods Our specific aim is to conduct a placebo-controlled RCT of depot NTX (d-NTX) for HIV+ prisoners with
OD who are transitioning to the community
150 subjects within CJS in NewHaven, Hartford and Springfield. Subjects will be randomized 2:1 to d-NTX
or d-placebo for 6 months and observed for 12 months
Participants HIV-infected prisonerswith opioid dependencewho are treatedwith depot naltrexone as they are transitioning
from the correctional to the community setting
150 participants.
Interventions Depot naltrexone versus placebo
Outcomes 6 and 12 months
HIV treatment (HIV-1 RNA levels, CD4 count, ART adherence, retention in care), substance abuse (time
to relapse to opioid use, % opioid negative urines, opioid craving), adverse side effects and HIV risk behavior
(sexual and drug-related risks)
The public health relevance is that outcomes from this study will establish the efficacy, safety and tolerability of
pharmacological therapy using naltrexone treatment among HIV+s and establish depot-naltrexone treatment
as an effective, evidence-based treatment for opioid dependence for released HIV+ prisoners
Starting date 2012
Contact information Yale University
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Agonist pharmacological vs no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Drug use (objective) 2 237 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.51, 1.00]
2 Drug use self reported
dichotomous
3 317 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.31, 1.18]
3 Drug use self reported
continuous
3 510 Std. Mean Difference (IV, Fixed, 95% CI) -0.62 [-0.85, -0.39]
4 Criminal activity dichotomous 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Arrests 1 62 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.32, 1.14]
4.2 Re-incarceration 3 472 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.36, 1.64]
5 Criminal activity continuous 1 51 Mean Difference (IV, Fixed, 95% CI) -74.21 [-133.53, -
14.89]
Comparison 2. Antagonist (Naltrexone) vs no pharmacological
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Criminal activity dichotomous 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Reincarceration 2 114 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.21, 0.74]
2 drug use (objective) 1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.28, 1.70]
Comparison 3. Methadone vs buprenorphine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self reported drug use
dichotomous
2 370 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.69, 1.55]
2 Self reported drug use
continuous
1 81 Mean Difference (IV, Fixed, 95% CI) 0.70 [-5.33, 6.73]
3 Criminal activity dichotomous 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 re incarceration 1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.83, 1.88]
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Comparison 4. Methadone vs diamorphine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 criminal activity dichotomous 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 arrest 1 825 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.03, 1.51]
Comparison 5. Methadone vs naltrexone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 self reported drug use continuous 1 44 Mean Difference (IV, Fixed, 95% CI) 4.60 [-3.54, 12.74]
2 criminal activity dichotomous 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 re incarceration 1 44 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.37, 3.26]
3 criminal activity continuous 1 44 Mean Difference (IV, Fixed, 95% CI) -0.5 [-8.04, 7.04]
Analysis 1.1. Comparison 1 Agonist pharmacological vs no intervention, Outcome 1 Drug use (objective).
Review: Pharmacological interventions for drug-using offenders
Comparison: 1 Agonist pharmacological vs no intervention
Outcome: 1 Drug use (objective)
Study or subgroup Pharmacological No pharmacological Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cropsey 2011 8/24 7/12 20.1 % 0.57 [ 0.27, 1.20 ]
Dolan 2003 33/106 39/95 79.9 % 0.76 [ 0.52, 1.10 ]
Total (95% CI) 130 107 100.0 % 0.72 [ 0.51, 1.00 ]
Total events: 41 (Pharmacological), 46 (No pharmacological)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours agonist Favours non pharm
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Analysis 1.2. Comparison 1 Agonist pharmacological vs no intervention, Outcome 2 Drug use self reported
dichotomous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 1 Agonist pharmacological vs no intervention
Outcome: 2 Drug use self reported dichotomous
Study or subgroup Pharmacological No pharmacological Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cropsey 2011 7/24 6/12 24.4 % 0.58 [ 0.25, 1.35 ]
Dolan 2003 41/129 92/124 37.9 % 0.43 [ 0.33, 0.56 ]
Dole 1969 10/12 15/16 37.7 % 0.89 [ 0.67, 1.18 ]
Total (95% CI) 165 152 100.0 % 0.61 [ 0.31, 1.18 ]
Total events: 58 (Pharmacological), 113 (No pharmacological)
Heterogeneity: Tau2 = 0.28; Chi2 = 18.04, df = 2 (P = 0.00012); I2 =89%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours agonist Favours non pharm
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Analysis 1.3. Comparison 1 Agonist pharmacological vs no intervention, Outcome 3 Drug use self reported
continuous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 1 Agonist pharmacological vs no intervention
Outcome: 3 Drug use self reported continuous
Study or subgroup Pharmacological No pharmacological
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dolan 2003 129 1 (5) 124 9 (19) 83.7 % -0.58 [ -0.83, -0.33 ]
Kinlock 2005 141 14.3 (27.19) 65 2801 (27.41) 0.1 % -101.85 [ -111.79, -91.92 ]
Kinlock 2007 20 65.63 (99.89) 31 125.29 (120.42) 16.2 % -0.52 [ -1.09, 0.05 ]
Total (95% CI) 290 220 100.0 % -0.62 [ -0.85, -0.39 ]
Heterogeneity: Chi2 = 399.08, df = 2 (P<0.00001); I2 =99%
Test for overall effect: Z = 5.31 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours agonist Favours non pharm
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Analysis 1.4. Comparison 1 Agonist pharmacological vs no intervention, Outcome 4 Criminal activity
dichotomous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 1 Agonist pharmacological vs no intervention
Outcome: 4 Criminal activity dichotomous
Study or subgroup Pharmacological No pharmacological Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Arrests
Kinlock 2005 8/24 21/38 100.0 % 0.60 [ 0.32, 1.14 ]
Subtotal (95% CI) 24 38 100.0 % 0.60 [ 0.32, 1.14 ]
Total events: 8 (Pharmacological), 21 (No pharmacological)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
2 Re-incarceration
Dolan 2003 143/191 137/191 45.4 % 1.04 [ 0.92, 1.18 ]
Dole 1969 3/12 15/16 25.6 % 0.27 [ 0.10, 0.72 ]
Kinlock 2005 7/24 9/38 29.0 % 1.23 [ 0.53, 2.87 ]
Subtotal (95% CI) 227 245 100.0 % 0.77 [ 0.36, 1.64 ]
Total events: 153 (Pharmacological), 161 (No pharmacological)
Heterogeneity: Tau2 = 0.32; Chi2 = 7.79, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.62), I2 =0.0%
0.01 0.1 1 10 100
Favours agonist Favours no pharm
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Analysis 1.5. Comparison 1 Agonist pharmacological vs no intervention, Outcome 5 Criminal activity
continuous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 1 Agonist pharmacological vs no intervention
Outcome: 5 Criminal activity continuous
Study or subgroup Pharmacological No pharmacological
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kinlock 2005 20 40.4 (89.88) 31 114.61 (126.01) 100.0 % -74.21 [ -133.53, -14.89 ]
Total (95% CI) 20 31 100.0 % -74.21 [ -133.53, -14.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours agonist Favours non pharm
Analysis 2.1. Comparison 2 Antagonist (Naltrexone) vs no pharmacological, Outcome 1 Criminal activity
dichotomous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 2 Antagonist (Naltrexone) vs no pharmacological
Outcome: 1 Criminal activity dichotomous
Study or subgroup Naltrexone Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Reincarceration
Cornish 1997 9/34 10/17 81.7 % 0.45 [ 0.23, 0.89 ]
Coviello 2010 2/31 9/32 18.3 % 0.23 [ 0.05, 0.98 ]
Subtotal (95% CI) 65 49 100.0 % 0.40 [ 0.21, 0.74 ]
Total events: 11 (Naltrexone), 19 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0036)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours naltrexone Favours non pharm
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Analysis 2.2. Comparison 2 Antagonist (Naltrexone) vs no pharmacological, Outcome 2 drug use
(objective).
Review: Pharmacological interventions for drug-using offenders
Comparison: 2 Antagonist (Naltrexone) vs no pharmacological
Outcome: 2 drug use (objective)
Study or subgroup Naltrexone no pharm treat Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Coviello 2010 6/31 9/32 100.0 % 0.69 [ 0.28, 1.70 ]
Total (95% CI) 31 32 100.0 % 0.69 [ 0.28, 1.70 ]
Total events: 6 (Naltrexone), 9 (no pharm treat)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours naltrexone Favours non pharm
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Analysis 3.1. Comparison 3 Methadone vs buprenorphine, Outcome 1 Self reported drug use dichotomous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 3 Methadone vs buprenorphine
Outcome: 1 Self reported drug use dichotomous
Study or subgroup methadone buprenorphine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Magura 2009 25/38 23/43 56.2 % 1.23 [ 0.86, 1.76 ]
Wright 2011 27/148 31/141 43.8 % 0.83 [ 0.52, 1.32 ]
Total (95% CI) 186 184 100.0 % 1.04 [ 0.69, 1.55 ]
Total events: 52 (methadone), 54 (buprenorphine)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.94, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours methadone Favours buprenorphine
Analysis 3.2. Comparison 3 Methadone vs buprenorphine, Outcome 2 Self reported drug use continuous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 3 Methadone vs buprenorphine
Outcome: 2 Self reported drug use continuous
Study or subgroup methadone buprenorphine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Magura 2009 38 14.4 (13.4) 43 13.7 (14.3) 100.0 % 0.70 [ -5.33, 6.73 ]
Total (95% CI) 38 43 100.0 % 0.70 [ -5.33, 6.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours methadone Favours buprenorphine
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Analysis 3.3. Comparison 3 Methadone vs buprenorphine, Outcome 3 Criminal activity dichotomous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 3 Methadone vs buprenorphine
Outcome: 3 Criminal activity dichotomous
Study or subgroup methadone buprenorphine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 re incarceration
Magura 2009 28/56 24/60 100.0 % 1.25 [ 0.83, 1.88 ]
Subtotal (95% CI) 56 60 100.0 % 1.25 [ 0.83, 1.88 ]
Total events: 28 (methadone), 24 (buprenorphine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours methadone Favours buprenorphine
Analysis 4.1. Comparison 4 Methadone vs diamorphine, Outcome 1 criminal activity dichotomous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 4 Methadone vs diamorphine
Outcome: 1 criminal activity dichotomous
Study or subgroup methadone diamorphine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 arrest
Lobmann 2007 155/406 128/419 100.0 % 1.25 [ 1.03, 1.51 ]
Subtotal (95% CI) 406 419 100.0 % 1.25 [ 1.03, 1.51 ]
Total events: 155 (methadone), 128 (diamorphine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.022)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours methadone Favours diamorphine
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Analysis 5.1. Comparison 5 Methadone vs naltrexone, Outcome 1 self reported drug use continuous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 5 Methadone vs naltrexone
Outcome: 1 self reported drug use continuous
Study or subgroup methadone naltrexone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lobmaier 2010 21 20.2 (12.56) 23 15.6 (14.97) 100.0 % 4.60 [ -3.54, 12.74 ]
Total (95% CI) 21 23 100.0 % 4.60 [ -3.54, 12.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours [experimental]met Favours [control]naltrexo
Analysis 5.2. Comparison 5 Methadone vs naltrexone, Outcome 2 criminal activity dichotomous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 5 Methadone vs naltrexone
Outcome: 2 criminal activity dichotomous
Study or subgroup methadone naltrexone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 re incarceration
Lobmaier 2010 5/21 5/23 100.0 % 1.10 [ 0.37, 3.26 ]
Subtotal (95% CI) 21 23 100.0 % 1.10 [ 0.37, 3.26 ]
Total events: 5 (methadone), 5 (naltrexone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [experimental]met Favours [control]naltrexo
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Analysis 5.3. Comparison 5 Methadone vs naltrexone, Outcome 3 criminal activity continuous.
Review: Pharmacological interventions for drug-using offenders
Comparison: 5 Methadone vs naltrexone
Outcome: 3 criminal activity continuous
Study or subgroup methadone naltrexone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lobmaier 2010 21 14.4 (13.11) 23 14.9 (12.34) 100.0 % -0.50 [ -8.04, 7.04 ]
Total (95% CI) 21 23 100.0 % -0.50 [ -8.04, 7.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours [experimental]met Favours [control]naltrexo
A D D I T I O N A L T A B L E S
Table 1. Table 1 summary of outcomes and comparisons
Study Setting Intervention Comparison
group
Follow-up
period
Outcome type Outcome
description
Bayanzadeh
2004
Prison Methadone treat-
ment in combina-
tion with
CBT and widely
focused on cop-
ing and problem-
solving skills
Non-meth-
adone drugs plus
standard psychi-
atric services and
therapeuticmedi-
cations
6 months Biological drug
use
Self-report drug
use
Drug use yes/no
Frequency
of drug injections
(percentage)
Syringe sharing
Morphine urine
analysis
Brown 2013 Community Methadone Primary care plus
sub-
oxone (buprenor-
phine and nalox-
one)
6 months
12 months
Biological drug
use
Self report drug
use
Fre-
quency and pat-
tern of daily drug
use
Addiction Sever-
ity Index (self re-
port).
Lite, HIV risk be-
haviours (RAB -
Risk Assessment
Battery short ver-
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Table 1. Table 1 summary of outcomes and comparisons (Continued)
sion), and health
services
utilization
Urine
drug screens were
collected as a part
of routine man-
agement
Cornish 1997 Community Naltrexone Routine parole/
probation
6 months and
during 6 months
of treatment
Criminal activity
dichotomous
% reincarcerated
during 6 months
of follow-up
Coviello 2010 Community Naltrexone Psychosocial
treatment only
6 months Biological drug
use dichotomous
Criminal activity
dichotomous
% positive urine
drug screen opi-
oids
% positive urine
drug screen co-
caine
% violating pa-
role/probation
Cropsey 2011 Community Buprenorphine Placebo End of treatment
3 months
Biological drug
use dichotomous
Self-report drug
use dichotomous
% positive urine
opiates
% self-report in-
jection drug use
Dolan 2003 Prison Pharmacological
(methadone)
Waiting list con-
trol
4 months
2 months
3 months
Biological drug
use continuous
Biological drug
use dichotomous
Self-report drug
use dichotomous
% hair positive
for morphine
% self-reported
any injection
% self-reported
heroin injection
Dole 1969 Prison Methadone Waiting list con-
trol.
At between 7 and
10 months
At 50 weeks
Biological drug
use continuous
Biological drug
use dichotomous
Self-report drug
use dichotomous
Heroin use
Reincarceration
Treatment reten-
tion
Employment
Howells 2002 Prison Methadone and
placebo
Lofexidine and
placebo
Post treatment Self report data
on withdrawl
Severity of psy-
chological depen-
dence
With-
drawal symptom
severity measured
using two with-
drawal scales: the
20-item With-
drawal Problems
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Table 1. Table 1 summary of outcomes and comparisons (Continued)
Scale (WPS), and
the eight item
Short Opiate
Withdrawal Scale
(SOWS)
Secondary out-
come measures
were rates and
timing of with-
drawal from the
detoxifica-
tion programme
so that the rela-
tionship between
failure to com-
plete detoxifica-
tion and sever-
ity of withdrawal
symptoms could
be measured
The Severity of
Dependency
Scale (SDS) was
also used to as-
sess the severity of
psychological as-
pects of drug de-
pendence
Kinlock 2007 Prison Counselling
+ methadone ini-
tiation pre-release
(a) and post-re-
lease (b)
Counselling only 1 month
3 months
6 months
12 months
Biological drug
use dichotomous
Self-report drug
use dichotomous
Criminal activity
dichotomous
% positive for
urine opioids
% positive for
urine cocaine
% self-reported 1
or more days
heroin
n used heroin for
entire 180-day
follow-up period
Re-incarcerated
Self-reported
criminal activity
Kinlock 2005 Prison Prison based levo
alpha
acetyl methanol
and transfer to
methadone after
release
untreated
controls
During 9 months Biological drug
use dichotomous
Self-report drug
use dichotomous
Criminal activity
dichotomous
Heroin use
Arrest
Re incarceration
Frequency of ille-
gal activity
Admission drug
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Table 1. Table 1 summary of outcomes and comparisons (Continued)
use
Average weekly
income
Lobmaier 2010 Prison Naltrexone Methadone 6 months Criminal activity
continuous
Criminal activity
dichotomous
Self-report drug
use continuous
Mean days of
criminal activity
% re-incarcerated
Mean days of
heroin use
Mean
days of benzodi-
azepine use
Mean days of am-
phetamine use
Lobmann 2007 Community Pharmacological
(diamorphine)
Methadone 12 months Criminal activity
dichotomous
% self-reported
criminal activity
% police-
recorded offences
Magura 2009 Prison Buprenorphine Methadone 3 months Criminal activity
dichotomous
Self-report drug
use continuous
Self-report drug
use dichotomous
% re-incarcerated
% arrested for
property crime
% arrested for
drug possession
Mean days of
heroin use
% any heroin/
opioid use
Wright 2011 Prison Buprenorphine Methadone 1 month
3 months
6 months post
detoxification
Biological drug
test
Self report official
drug records
Abstinence from
illicit opiates at 8
days post detoxi-
fication, as indi-
cated by a urine
test
If the participant
had been re-
leased, local com-
munity drugs ser-
vice records were
accessed to verify
abstinence
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
MEDLINE search
1. exp “Substance-Related-Disorders”/
2. ((drug or substance) adj (abuse* or addict* or dependen* or misuse*)).ti,ab
3. (drug* adj (treat* or intervention* or program*)
4. substance near (treat* or intervention* or program*)
5.(detox* or methadone) in ti,ab
6. narcotic* near (treat* or intervention* or program*)
7. 1 or 2 or 3 or 4 or 5 or 6
8. prison*. ti,ab
9. exp “Prisoners”/
10. offender* or criminal* or inmate* or convict* or probation* or remand or felon*).ti,ab
11. exp “Prisons”/
12. 8 or 9 or 10 or 11
13. 7 and 12
Appendix 2. EMBASE search strategy
Embase search
1. (detox$ or methadone or antagonist prescri$).ti,ab.
2. detoxification/ or drug detoxification/ or drug withdrawal/ or drug dependence treatment/ or methadone/ ormethadone treatment/
or diamorphine/ or naltrexone/
3. (diamorphine or naltrexone or therapeutic communit$).ti,ab
4. morality/
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(Continued)
5. (motivational interview$ or motivational enhancement).ti,ab
6. (counselling or counseling).ti,ab.
7. exp counseling/
8. (psychotherap$ or cognitive behavioral or cognitive behavioural).ti,ab
9. exp psychotherapy/
10. (moral adj3 training).ti,ab.
11. (cognitive restructuring or assertiveness training).ti,ab
12. reinforcement/ or self monitoring/ or self control/
13. (relaxation training or rational emotive or family relationship therap$).ti,ab
14. social learning/ or withdrawal syndrome/ or coping behavior/
15. (community reinforcement or self monitoring or self control or self management or interpersonal skills).ti,ab
16. (goal$ adj3 setting).ti,ab.
17. (social skills adj3 training).ti,ab.
18. anger/ or lifestyle/
19. (basic skills adj3 training).ti,ab.
20. (relapse adj3 prevent$).ti,ab.
21. (craving adj3 (minimi$ or reduc$)).ti,ab.
22. (trigger or triggers or coping skills or anger management or group work).ti,ab
23. (lifestyle adj3 modifi$).ti,ab.
24. (high intensity training or resettlement or throughcare or aftercare or after care).ti,ab
25. aftercare/ or halfway house/
26. (brief solution or brief intervention$ or minnesota program$ or 12 step$ or twelve step$).ti,ab
27. (needle exchange or nes or syringe exchange or dual diagnosis or narcotics anonymous).ti,ab
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(Continued)
28. self help/ or support group/
29. (self-help or selfhelp or self help or outreach or bail support or arrest referral$).ti,ab
30. exp urinalysis/ or rehabilitation/ or rehabilitation center/
31. (diversion or dtto or dttos or drug treatment or testing order$ or carat or carats).ti,ab
32. (combined orders or drug-free or drug free).ti,ab.
33. (peer support or evaluation$ or urinalysis or drug testing or drug test or drug tests).ti,ab
34. ((rehab or rehabilitation or residential or discrete) adj2 (service$ or program$)).ti,ab
35. (asro or addressing substance$ or pasro or prisons addressing or acupuncture or shock or boot camp or boot camps).ti,ab
36. (work ethic camp$ or drug education or tasc or treatment accountability).ti,ab
37. exp acupuncture/
38. or/1-36
39. (remand or prison or prisoner or prisoners or offender$ or criminal$ or probation or court or courts).ti,ab
40. (secure establishment$ or secure facilit$).ti,ab.
41. (reoffend$ or reincarcerat$ or recidivi$ or ex-offender$ or jail or jails or goal or goals).ti,ab
42. (incarcerat$ or convict or convicts or convicted or felon or felons or conviction$ or revocation or inmate$ or high security).ti,ab
43. criminal justice/ or custody/ or detention/ or prison/ or prisoner/ or offender/ or probation/ or court/ or recidivism/ or crime/ or
criminal behavior/ or punishment/
44. or/39-43
45. 38 and 44
46. (substance abuse$ or substance misuse$ or substance use$).ti,ab
47. (drug dependanc$ or drug abuse$ or drug use$ or drug misuse$ or drug addict$).ti,ab
48. (narcotics adj3 (addict$ or use$ or misuse$ or abuse$)).ti,ab
49. (chemical dependanc$ or opiates or heroin or crack or cocaine or amphetamines or addiction or dependance disorder or drug
involved).ti,ab
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(Continued)
50. substance abuse/ or drug abuse/ or analgesic agent abuse/ or drug abuse pattern/ or drug misuse/ or intravenous drug abuse/ or
multiple drug abuse/
51. addiction/ or drug dependence/ or narcotic dependence/ or exp narcotic agent/ or narcotic analgesic agent/
52. opiate addiction/ or heroin dependence/ or morphine addiction/
53. cocaine/ or amphetamine derivative/ or psychotropic agent/
54. or/46-53
55. 45 and 54
Appendix 3. PsycInfo search strategy
PsycInfo
1. (detoxification in de) or (drug withdrawal in de)
2. (drug usage screening in de) or (methadone maintenance) in de
3. explode “Narcotic-Antagonists” in DE
4. 1 or 2 or 3
5. (counseling in de) or (explode “psychotherapeutic-counseling” in de)
6. (explode “cognitive-therapy” in de) or (explode “psychotherapeutic-techniques” in de)
7. (cognitive restructuring in de) or (assertiveness training in de)
8. explode “relaxation-therapy” in de
9. (rational emotive therapy in de) or (rational-emotive therapy in de)
10. (explode “self monitoring” in de) or (explode self-monitoring) in de
11. (goal setting in de) or (self control in de) or (explode “self-management” in de)
12. (social skills in de) or (relapse prevention in de) or (craving in de) or (coping behavior in de)
13. (anger control in de) or (explode “group-psychotherapy” in de) or (brief psychotherapy in de)
14. (explode “behavior-modification” in de) or (posttreatment followup in de) or (aftercare in de)
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(Continued)
15. (halfway houses in de) or (twelve step programs in de)
16. (dual diagnoses in de) or (explode “self help techniques” in de) or (outreach programs in de) or (court referrals in de)
17. (peer pressure in de) or (urinalysis in de)
18. (drug rehabilitation in de) or (residential care institutions in de) or (acupuncture in de) or (drug education in de)
19. (detox* or methadone or antagonist prescri* or diamorphine or naltrexone or therapeutic communit*) in ti,ab
20. (motivational interview* or motivational enhancemen* or counseling or psychotherapy or psychotherapies) in ti,ab
21. (cognitive behav* or cognitive therapy or cognitive therapies or moral training or cognitive restructuring) in ti,ab
22. (assertiveness training or relaxation training or relaxation therapy or relaxation therapies) in ti,ab
23. (rational emotive therap* or rational emotive behav* therap* or family relationship therap* or community reinforcement) in ti,ab
24. (self-monitor* or self monitor* or goal setting or self control or self-control or self management or self-management) in ti,ab
25. (interpersonal skills training or social skills training or basic skills training) in ti,ab
26. (relapse with prevent*) in ti,ab
27. (craving near reduc*) in ti,ab
28. craving with (reduc* in ti,ab)
29. (trigger* or coping skills or anger management or group work or lifestyle modif* or high intensity training or resettlement) in ti,
ab
30. (throughcare or aftercare or after care or brief solution* or brief intervention*) in ti,ab
31. (minnesota or 12 step* or twelve step* or needle exchange or nes or syringe exchange or dual diagnosis) in ti,ab
32. (narcotics anonymous or self-help or self help or outreach or bail support or arrest referral*) in ti,ab
33. (diversion or dtto* or testing order* or carat* or counseling assessment referral or combined order or combined orders or drug
free wing* or drug free environment*) in ti,ab
34. (peer support or user evaluations or urinalysis or urinalyses or mandatory drug test* or rehabilitation or discrete service* or discrete
program*) in ti,ab
35. (residential program* or residential scheme* or asro or addressing substance* or pasro or prisons addressing substance) in ti,ab
36. (acupuncture or shock or boot camp* or work ethic or drug education or tasc or treatment accountability) in ti,ab
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37. or/4-36
38. (secure facilities or convict* or revocation or inmate* or high security) in ti,ab
39. (prisoners in de) or (explode “correctional-institutions” in de)
40. (perpetrators in de) or (explode criminals in de)
41. (probation in de) or (parole in de) or (incarceration in de) or (recidivism in de) or (criminal conviction in de) or (crime in de)
42. (remand or prison* or offender* or criminal* or probation or court or courts or secure establishment* or reoffend* or reincarcerat*
or recidivi* or ex-offender* or jail or jails or incarcerat*) in ti,ab
43. (drug abuse in de) or (explode “inhalant-abuse” in de) or (explode “drug-dependency” in de)
44. (polydrug abuse in de) or (drug abuse in de) or (intravenous drug usage in de)
45. (narcotic drugs in de) or (heroin in de) or (cocaine in de) or (explode amphetamine in de)
46. (substance abuse* or substance misuse* or substance user*) in ti,ab
47. (drug dependen* or drug abuse* or drug misuse* or drug addict* or drug use) in ti,ab
48. (narcotic abuse* or narcotic misuse* or chemical dependen* or opiate misuse* or opiate abuse*) in ti,ab
49. (heroin use* or heroin addict* or heroin misuse* or heroin abuse*) in ti,ab
50. (crack use* or crack addict* or crack misuse* or crack abuse*) in ti,ab
51. (cocaine use* or cocaine addict* or cocaine misuse* or cocaine abuse*) in ti,ab
52. (amphetamine* use* or amphetamine* addict* or amphetamine* misuse* or amphetamine* abuse*) in ti,ab
53. (dependence disorder or drug involved or dug-involved) in ti,ab
54. #38 or #39 or #40 or #41 or #42
55. #4 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53
56. #37 and #54 and #55
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Appendix 4. SPECTRA search strategy
SPECTRA search
1. {remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment} or {secure facilit} or
{reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict} or {high security}
or {law enforcement}
{remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment} or {secure facilit} or
{reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict} or {high security}
or {law enforcement}
2. {substance} or {dependenc} or {drug abuse} or {drug use} or {drug misuse} or {addict}
All indexed fields: {remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment} or
{secure facilit} or {reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict}
or {high security} or {law enforcement}
OR
All unindexed fields: {remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment}
or {secure facilit} or {reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict}
or {high security} or {law enforcement}
AND
All unindexed fields: {substance} or {dependenc} or {drug abuse} or {drug use} or {drug misuse} or {addict} or {narcotics} or {opiates}
or {heroin} or {crack} or {cocaine} or {amphetamines} or {drug involved} or {substance-related} or {amphetamine-related} or {cocaine-
related} or {marijuana} or {opioid} or {street drug} or {designer drug}
3. narcotics
4. opiates
5. heroin
6. {crack}
7. cocaine
8. amphetamines
9. drug involved
10. substance-related
11. amphetamine-related
12. cocaine-related
13. marijuana
14. opioid
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15. street drug
16. designer drug
17. 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
18. 1 AND 17
Appendix 5. PASCAL. SciSearch, Social SciSSciSearch, Wilson Applied Science and Technology
Abstracts search strategy
PASCAL search
1. (DETOX? OR METHADONE OR ANTAGONIST()PRESCRI?)/TI,AB
2. METHADONE/DE OR NALTREXONE/DE
3. (DIAMORPHINE OR NALTREXONE)/TI,AB
4. THERAPEUTIC()COMMUNITY/DE OR THERAPEUTIC()COMMUNIT?)/TI,AB
5. (MOTIVATIONAL()INTERVIEW? ORMOTIVATIONAL()ENHANCEMENT)/TI,AB
6. (COUNSELLING OR COUNSELING)/TI,AB
7. COUNSELING/DE
8. (PSYCHOTHERAP? OR COGNITIVE()BEHAVIORAL OR COGNITIVE()BEHAVIOURAL)/TI,AB
9. PSYCHOTHERAPY!/DE
10. (MORAL(3W)TRAINING)/TI,AB
11. (COGNITIVE()RESTRUCTURING OR ASSERTIVENESS()TRAINING)/TI,AB
12. ASSERTIVENESS/DE OR RELAXATION()TECHNIQUES/DE
13. (RELAXATION()TRAINING OR RATIONAL()EMOTIVE OR FAMILY()RELATIONSHIP()THERAP?)/TI,AB
14. FAMILY()RELATIONS/DE
15. (COMMUNITY()REINFORCEMENT OR SELF()MONITORING OR SELF()CONTROL OR SELF()MANAGEMENT
OR INTERPERSONAL()SKILLS)/TI,AB
16. (GOAL?(3W)SETTING)/TI,AB
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(Continued)
17. (SOCIAL(3W)TRAINING)/TI,AB
18. SOCIAL RESPONSIBILITY/DE
19. (BASIC()SKILLS(3W)TRAINING)/TI,AB
20. (RELAPSE(3W)PREVENT?)/TI,AB
21. (CRAVING(3W)(MINIMI? OR REDUC?))/TI,AB
22. (TRIGGER OR TRIGGERS OR COPING()SKILLS OR ANGER()MANAGEMENT OR GROUP()WORK)/TI,AB
23. (LIFESTYLE(3W)MODIFI?)/TI,AB
24. (HIGH()INTENSITY()TRAININGORRESETTLEMENTORTHROUGHCARE ORAFTERCAREORAFTER()CARE)
/TI,AB
25. ADAPTATION,-PSYCHOLOGICAL!/DE OR ANGER/DE OR LIFE()STYLE/DE OR AFTER()CARE/DE ORHALFWAY
()HOUSES/DE
26. (BRIEF()SOLUTION OR BRIEF()INTERVENTION? OR MINNESOTA()PROGRAM? OR 12()STEP? OR TWELVE()
STEP?)/TI,AB
27. (NEEDLE()EXCHANGE OR NES OR SYRINGE()EXCHANGE OR DUAL()DIAGNOSIS OR NARCOTICS()ANONY-
MOUS)/TI,AB
28. NEEDLE-EXCHANGE()PROGRAMS/DE
29. (SELF-HELP OR SELFHELP OR SELF()HELP OR OUTREACH OR BAIL()SUPPORT OR ARREST()REFERRAL?)/TI,
AB
30. SELF-HELP()GROUPS/DE OR URINALYSIS/DE OR SUBSTANCE()ABUSE()DETECTION/DE
31. (DIVERSION ORDTTO ORDTTOS ORDRUG()TREATMENT OR TESTING()ORDER? ? OR CARAT OR CARATS)
/TI,AB
32. (COMBINED()ORDERS OR DRUG-FREE OR DRUG()FREE)/TI,AB
33. (PEER()SUPPORT OR EVALUATION? ? OR URINALYSIS OR DRUG()TESTING OR DRUG()TEST? ?)/TI,AB
34. ((REHAB OR REHABILITATION OR RESIDENTIAL OR DISCRETE)(2W)(SERVICE? ? OR PROGRAM?))/TI,AB
35. (ASROORADDRESSING()SUBSTANCE?ORPASROORPRISONS()ADDRESSINGORACUPUNCTUREORSHOCK
OR BOOT()CAMP OR BOOT()CAMPS)/TI,AB
36. (WORK()ETHIC()CAMP? ? OR DRUG()EDUCATION OR TASC OR TREATMENT()ACCOUNTABILITY)/TI,AB
37. ACUPUNCTURE-THERAPY!/DE OR ACUPUNCTURE/DE OR HEALTH()EDUCATION/DE OR SUBSTANCE()
ABUSE()TREATMENT()CENTERS/DE
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38. S1:S3
39. S4:S37
40. S38 AND S39
40. (REMAND OR PRISON OR PRISONER OR PRISONERS OR OFFENDER? ? OR CRIMINAL? ? OR PROBATION OR
COURT OR COURTS)/TI,AB
41. (SECURE()ESTABLISHMENT? ? OR SECURE()FACILIT?)/TI,AB
42. (REOFFEND? OR REINCARCERAT? OR RECIDIVI? OR EX()OFFENDER? ? OR JAIL OR JAILS)/TI,AB
43. (INCARCERAT? OR CONVICT OR CONVICTS OR CONVICTED OR FELON? ? OR CONVICTION? ? OR REVO-
CATION OR INMATE? ? OR HIGH()SECURITY)/TI,AB
44. PRISONERS/DE OR LAW()ENFORCEMENT/DE OR JURISPRUDENCE/DE
45. S40:S44
46. S40 AND S45
47. (SUBSTANCE()ABUSE? OR SUBSTANCE()MISUSE? OR SUBSTANCE()USE?)/TI,AB
48. (DRUG()DEPENDANC? OR DRUG()ABUSE? OR DRUG()USE? OR DRUG()MISUSE? OR DRUG()ADDICT?)/TI,AB
49. (NARCOTICS(3W)(ADDICT? OR USE? OR MISUSE? OR ABUSE?))/TI,AB
50. (CHEMICAL()DEPENDANC? OR OPIATES OR HEROIN OR CRACK OR COCAINE OR AMPHETAMINES OR
ADDICTION OR DEPENDENCE()DISORDER OR DRUG()INVOLVED)/TI,AB
51. SUBSTANCE-RELATED()DISORDERS/DE OR AMPHETAMINE-RELATED()DISORDERS/DE OR COCAINE-RE-
LATED()DISORDERS/DE OR MARIJUANA ()ABUSE/DE
52. OPIOID-RELATED-DISORDERS!/DE OR PHENCYCLIDINE()ABUSE/DE OR SUBSTANCE()ABUSE()INTRA-
VENOUS/DE
53. STREET()DRUGS/DE OR DESIGNER()DRUGS/DE OR NARCOTICS/DE
54. COCAINE!/DE OR AMPHETAMINES!/DE OR ANALGESICS()OPIOID/DE
55. S47:S54
56. S46 AND S55
57. (DETOXIFICATION OR METHADONE OR ANTAGONIST-PRESCRIBING)/DE FROM 144,34,434,7,99,65,35,6
58. (DIAMORPHINE OR NALTREXONE)/DE FROM 144,34,434,7,99,65,35,6
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59. THERAPEUTIC-COMMUNITY)/DE FROM 144,34,434,7,99,65,35,6
60. (MOTIVATIONAL-INTERVIEW OR MOTIVATIONAL-ENHANCEMENT)/DE FROM 144,34,434,7,99,65,35,6
61. (COUNSELLING OR COUNSELING)/DE FROM 144,34,434,7,99,65,35,6
62. (PSYCHOTHERAPY! OR COGNITIVE-BEHAVIORAL OR COGNITIVE-BEHAVIOURAL)/DE FROM 144,34,434,7,
99,65,35,6
63. (MORAL-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
64. (COGNITIVE-RESTRUCTURING OR ASSERTIVENESS-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
65. (RELAXATION-TRAINING OR RATIONAL-EMOTIVE OR FAMILY-RELATIONSHIP-THERAPY)/DE FROM 144,34,
434,7,99,65,35,6
66. FAMILY-RELATIONS/DE
67. (COMMUNITY-REINFORCEMENT OR SELF-MONITORING OR SELF-CONTROL OR SELF-MANAGEMENTOR
INTERPERSONAL-SKILLS)/DE FROM 44,34,434,7,99,65,35,6
68. (GOAL-SETTING)/DE FROM 144,34,434,7,99,65,35,6
69. (SOCIAL-SKILLS-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
70. SOCIAL-RESPONSIBILITY/DE
71. (BASIC-SKILLS-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
72. (RELAPSE-PREVENTION)/DE FROM 144,34,434,7,99,65,35,6
73. CRAVING/DE FROM 144,34,434,7,99,65,35,6
74. (TRIGGER OR COPING-SKILLS OR ANGER-MANAGEMENT OR GROUP-WORK)/DE FROM 144,34,434,7,99,65,
35,6
75. (LIFESTYLE-MODIFICATION)/DE FROM 144,34,434,7,99,65,35,6
76. (HIGH-INTENSITY-TRAINING OR RESETTLEMENT OR THROUGHCARE OR AFTERCARE OR AFTER-CARE)/
DE FROM 144,34,434,7,99,65,35,6
77. (BRIEF-SOLUTION OR BRIEF-INTERVENTIONS OR MINNESOTA-PROGRAM OR 12-STEP-PROGRAM OR
TWELVE-STEP-PROGRAM)/DE FROM 144,34,434,7,99,65,35,6
77. (NEEDLE-EXCHANGE OR SYRINGE-EXCHANGE OR DUAL-DIAGNOSIS OR NARCOTICS-ANONYMOUS)/DE
FROM 144,34,434,7,99,65,35,6
79. (SELF-HELP OR OUTREACH OR BAIL-SUPPORT OR ARREST-REFERRAL)/DE FROM 144,34,434,7,99,65,35,6
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80. (DRUG-TREATMENT OR TESTING-ORDERS OR CARAT)/DE FROM 144,34,434,7,99,65,35,6
81. (COMBINED-ORDERS OR DRUG-FREE)/DE FROM 144,34,434,7,99,65,35,6
82. (PEER-SUPPORT OR EVALUATION OR URINALYSIS OR DRUG-TESTING OR DRUG-TESTS)/DE FROM 144,34,
434,7,99,65,35,6
83. (REHABILITATION OR RESIDENTIAL OR DISCRETE-SERVICES)/DE FROM 144,34,434,7,99,65,35,6
84. (ASRO OR PASRO ACUPUNCTURE OR BOOT-CAMP)/DE FROM 144,34,434,7,99,65,35,6
85. (WORK-ETHIC-CAMP OR DRUG-EDUCATION OR TASC OR TREATMENT-ACCOUNTABILITY)/DE FROM 144,
34,434,7,99,65,35,6
86. (REMAND OR PRISON OR PRISONER OR PRISONERS OR OFFENDER OR OFFENDERS OR CRIMINAL OR
CRIMINALS OR PROBATION OR COURT OR COURTS)/DE FROM 144,34,434,7,99,65,35,6
87. (SECURE-ESTABLISHMENTS OR SECURE-FACILITY)/DE FROM 144,34,434,7,99,65,35,6
88. (REOFFENDERS OR REINCARCERATION OR RECIDIVISM OR EX-OFFENDERS OR JAILS)/DE FROM 144,34,
434,7,99,65,35,6
89. (INCARCERATIONORCONVICTORCONVICTSORFELONORFELONSORCONVICTIONSORREVOCATION
OR INMATE OR INMATES OR HIGH-SECURITY)/DE FROM 144,34,434,7,99,65,35,6
90. (SUBSTANCE-ABUSE OR SUBSTANCE-MISUSE OR SUBSTANCE-USE)/DE FROM 144,34,434,7,99,65,35,6
91. (DRUG-DEPENDANCEORDRUG-DEPENDENCYORDRUG-ABUSEORDRUG-MISUSEORDRUG-ADDICT OR
DRUG-ADDICTION)/DE FROM 144,34,434,7,99,65,35,6
92. (CHEMICAL-DEPENDANCY OR OPIATE-DEPENDENCY OR HEROIN-DEPENDENCY OR CRACK-DEPEN-
DENCY OR COCAINE-DEPENDENCY OR AMPHETAMINES OR ADDICTION OR DEPENDENCE-DISORDER OR
DRUG-INVOLVED)/DE FROM 144,34,434,7,99,65,35,6
93. S40 OR S57:S85
94. S45 OR S86:S89
95. S55 OR S90:S92
96. S93 AND S94 AND S95
97. S96/1980-2004
95Pharmacological interventions for drug-using offenders (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 6. The CENTRAL Register of Controlled trials search strategy
CENTRAL search
1. prison*
2. offender*
3. (criminal* or probation or court*)
4. (secure next establishment*)
5. reoffend*
6. reincarcerat*
7. recidiv*
8. exoffend*
9. (jail or jails or incarcerat*)
10. (secure next facilit*)
10(secure next facilit*)
11. (convict* or revocation or inmate* or (high next security))
12. PRISONERS
13. LAW ENFORCEMENT
14. JURISPRUDENCE
15. CRIME
16. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
17. SUBSTANCE-RELATED DISORDERS
18. ((substance or drug*) next (abuse* or misuse* or dependen*or use* or addict*))
19. (narcotics or chemical or opiate) next (dependen* or addict* or abuse* or misuse*))
20. ((heroin) next (addict* or dependen* or misuse* or abuse*))
21. ((crack) next (addict* or dependen* or misuse* or abuse* or use*))
22. ((cocaine next addict*) or (cocaine next dependenc*) or (cocaine next misuse*) or (cocaine next abuse*) or (cocaine next use*))
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23. ((amphetamine*) next (addict* or dependen* or misuse* or abuse* or use*))
24. (addicts or (dependence next disorder) or (drug next involved))
25. (street next drugs)
26. STREET DRUGS
27. DESIGNER DRUGS
28. NARCOTICS
29. COCAINE
30. AMPHETAMINES
31. ANALGESICS ADDICTIVE
32. ANALGESICS OPIOID
33. PSYCHOTROPIC DRUGS
34. opioid* or opiat*
35. #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34
35. (#16 and #35)
Appendix 7. SIGLE search strategy
SIGLE
1. ((reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab)
2. ((remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab
3. ((drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab
4. ((drug abuse* or drug misuse* or drug use*) in ti,ab
5. ((substance abuse* or substance misuse* or substance use*) in ti,ab
6. ((detox* or methadone maintenance or methadone prescri* or antagonist prescri* or dimorphine or naltrexone) in ti,ab
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7. ((dependence disorder or drug involved) in ti,ab
8. ((amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab
9. ((cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab
10. ((crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab
11. ((heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab
12. ((chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab
13. #1 or #2
14. #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
15. #13 and #14
Appendix 8. Sociological Abstracts search strategy
Sociological Abstrac
1. remand in de
2. detention in de
3. prisoners in de
4. prisons in de
5. offenders in de
6. parole in de
7. probation in de
8. correctional system in de
9. courts in de
10. imprisonment in de
11. criminal justice in de
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12. criminal proceedings in de
13. recidivism in de
14. jail in de
15. institutionalization (persons) in de
16. conviction/convictions in de
17. (remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab
18. (reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab
19. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19
20. substance abuse in de
21. explode “Drug-Abuse” in DE
22. “Drug-Injection” in DE
23. explode “Narcotic-Drugs” in DE
24. “Cocaine-” in DE
25. “Addiction-” in DE
26. explode “Psychedelic-Drugs” in DE
27. (substance abuse* or substance misuse* or substance use*) in ti,ab
28. (drug abuse* or drug misuse* or drug use*) in ti,ab
29. (drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab
30. (chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab
31. (heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab
32. (crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab
33. (cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab
34. (amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab
35. (dependence disorder or drug involved) in ti,ab
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36. #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35
37. #19 and #36
38. “Detoxification-” in DE
39. “Methadone-Maintenance” in DE
40. “Counseling-” in DE
41. “Psychotherapy-” in DE
42. “Assertiveness-” in DE
43. (detoxification in de) or (methadone maintenance in de) or (treatment programs in de)
44. (counseling in de) or (psychotherapy in de) or (assertiveness in de) or (group therapy in de) or (goals in de) or (self control in de)
45. (interpersonal communication in de) or (social interaction in de) or (social competence in de) or (coping in de)
46. (social behavior in de) or (group work in de) or (lifestyle in de)
47. (after care in de) or (support networks in de) or (self help in de) or (self help groups in de) or (outreach programmes in de)
48. (outreach programs in de) or (referral in de) or (delinquency prevention in de) or (diversion/diversions in de)
49. (peer groups in de) or (peer influence in de) or (drug use screening in de) or (rehabilitation in de) or (work experience in de)
50. (detox* or methadone maintenance or methadone prescri* or antagonist prescri* or dimorphine or naltrexone) in ti,ab
51. (therapeutic communit* or motivational interview* or motivational enhance* or counseling or counselling or psychotherapy or
cognitive behavi*) in ti,ab
52. (moral training or cognitive restructuring or assertiveness training or relaxation training) in ti,ab
53. (rational-emotive or rational emotive or family relationship therap* or community reinforcement or self monitoring or goal setting
or self control training) in ti,ab
54. (self management or interpersonal skills or social skills or basic skills or relapse prevent* or prevent* relapse or craving reduc* or
reduc* craving) in ti,ab
55. (trigger* or coping skills or anger management or group work or lifestyle modif* or high intensity training or resettlement or
throughcare) in ti,ab
56. (aftercare or after care or brief solution or brief intervention* or 12 step* or twelve step* or minnesota program* or needle exchange
or nes) in ti,ab
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57. (syringe exchange or dual diagnosis or narcotics anonymous or self help or selfhelp or outreach or bail support) in ti,ab
58. (arrest referral* or diversion or dtto or dttos or drug treatment or carat or carats or counseling assessment or combined orders) in
ti,ab
59. (drug-free or drug free or peer support or evaluation* or urinalysis or drug testing or drug use screen* or rehabilitation or discrete
service* or discrete program*) in ti,ab
60. (residential program* or residential scheme* or residential service*) in ti,ab
61. (asro or addressing substance or pasro or prisons addressing or acupuncture or shock or boot camp*) in ti,ab
62. (work ethic or drug education or tasc or treatment accountability) in ti,ab
63. #38 or #39 #or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #
55 or #56 or #57 or #58 or #59 or #60 or #61 or #62
64. #37 and #63
Appendix 9. ASSIA search strategy
ASSIA search
1. remand
2. prison or prisoner or prisoners
3. offender*
4. criminal*
5. probation
6. court or courts
7. tribunal or tribunals
8. secure establishment*
9. secure facilit*
10. reoffend*
11. reincarcerat*
12. recidivi*
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13. ex-offender*
14. jail or jails
15. incarcerat*
16. convict or convicts
17. convicted
18. felon or felons
19. conviction*
20. reconviction*
21. high security
22. law enforcement
23. Substance abuse* or substance misuse* or substance use*
24. drug dependanc* or drug abuse* or drug use*
25. drug misuse* or drug addict*
26. narcotics addict* narcotics use* narcotics misuse* narcotics abuse*
27. chemical dependanc*
28. opiates
29. heroin
30. crack
31. cocaine
32. amphetamines
33. cocaine
34. addiction
35. dependence disorder*
36. drug involved
37. Substance-related disorders
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38. amphetamine-related disorders
39. cocaine-related disorders
40. marijuana abuse
41. opioid-related disorders
42. street drugs
43. designer drugs
44. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
45. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
46. 44 and 45
Appendix 10. HMIC search strategy
HMIC
1. remand in de
2. detention in de
3. prisoners in de
4. prisons in de
5. offenders in de
6. parole in de
7. probation in de
8. correctional system in de
9. courts in de
10. imprisonment in de
11. criminal justice in de
12. criminal proceedings in de
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13. recidivism in de
14. jail in de
15. institutionalization (persons) in de
16. conviction/convictions in de
17. (remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab
18. (reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab
19. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
20. substance abuse in de
21. explode “Drug-Abuse” in DE
22. “Drug-Injection” in DE
23. explode “Narcotic-Drugs” in DE
24. “Cocaine-” in DE
25. “Addiction-” in DE
26. explode “Psychedelic-Drugs” in DE
27. (substance abuse* or substance misuse* or substance use*) in ti,ab
28. (drug abuse* or drug misuse* or drug use*) in ti,ab
29. (drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab
30. (chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab
31. (heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab
32. (crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab
33. (cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab
34. (amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab
35. (dependence disorder or drug involved) in ti,ab
36. #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35
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37. #19 and #36
Appendix 11. National Research Register search strategy
NRR search
1. REMAND
2. PRISON*
3. OFFENDER*
4. ((CRIMINAL* or PROBATION) or COURT) or COURTS)
5. (SECURE next ESTABLISHMENT*)
6. REOFFEND*
7. REINCARCERAT*
8. RECIDIV*
9. EXOFFEND*
10. ((JAIL or JAILS) or INCARCERAT*)
11. (SECURE next FACILIT*)
12. (((CONVICT* or REVOCATION) or INMATE*) OR (HIGH next SECURITY))
13. PRISONERS:ME
14. LAW-ENFORCEMENT:ME
15. JURISPRUDENCE:ME
16. CRIME:ME
17. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
18. #11 or #12 or #13 or #14 or #15 or #16
19. #17 or #18
20. ((SUBSTANCE next ABUSE*) or (SUBSTANCE next MISUSE*)) OR (DRUG NEXTDEPENDENC*)) OR (DRUG NEXT
ABUSE*)) OR (DRUG NEXT MISUSE*)) OR (DRUG NEXT USE*)) OR (DRUG NEXT ADDICTION))
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21. ((NARCOTICS or (CHEMICAL next DEPENDENC*)) OR (OPIATE NEXT ADDICT*)) OR (OPIATE NEXT DEPEN-
DENC*)) OR (OPIATE NEXT ABUSE*)) OR (OPIATE NEXT MISUSE*))
22. ((HEROIN next ADDICT*) or (HEROIN next DEPENDENC*)) OR (HEROIN NEXT MISUSE*)) OR (HEROIN NEXT
ABUSE*))
23. ((CRACK next ADDICT*) or (CRACK next DEPENDENC*)) OR (CRACK NEXT MISUSE*)) OR (CRACK NEXT
ABUSE*)) OR (CRACK NEXT USE*))
24. ((COCAINE next ADDICT*) or (COCAINE next DEPENDENC*)) OR (COCAINE NEXT MISUSE*)) OR (COCAINE
NEXT ABUSE*)) OR (COCAINE NEXT USE*))
25. ((AMPHETAMINE* next ADDICT*) or (AMPHETAMINE* next DEPENDENC*)) OR (AMPHETAMINE* NEXT MIS-
USE*)) OR (AMPHETAMINE* NEXT ABUSE*)) OR (AMPHETAMINE* NEXT USE*))
26. ((ADDICTS or (DEPENDENCE next DISORDER)) OR (DRUG NEXT INVOLVED))
27. (SUBSTANCE-RELATED and DISORDERS:ME)
28. SUBSTANCE-RELATED-DISORDERS:ME
29. AMPHETAMINE-ABUSE:ME
30. COCAINE-ABUSE:ME
31. MARIJUANA-ABUSE:ME
32. OPIOID-RELATED-DISORDERS:ME
33. PHENCYCLIDINE-ABUSE:ME
34. SUBSTANCE-ABUSE-INTRAVENOUS:ME
35. SUBSTANCE-WITHDRAWAL-SYNDROME:ME
36. (STREET next DRUGS)
38. STREET-DRUGS:ME
39. DESIGNER-DRUGS:ME
40. NARCOTICS:ME
41. (COCAINE:ME or AMPHETAMINES:ME)
42. ANALGESICS-ADDICTIVE:ME
43. ANALGESICS-OPIOID:ME
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44. PSYCHOTROPIC-DRUGS:ME
45. #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37
or #38 or #39 or #40 or #41 or #42 or #43 or #44
46. 19 and 45
Appendix 12. PAIS search strategy
PAIS
1. ((reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab)
2. ((remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab)
3. ((drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab)
4. ((drug abuse* or drug misuse* or drug use*) in ti,ab) or ((substance abuse* or substance misuse* or substance use*) in ti,ab)
5. ((detox* or methadone maintenance or methadone prescri* or antagonist prescri* or dimorphine or naltrexone) in ti,ab)
6. ((dependence disorder or drug involved) in ti,ab)
7. ((amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab)
8. ((cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab)
9. ((crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab)
10. ((heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab)
11. ((chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab)
12. ((moral training or cognitive restructuring or assertiveness training or relaxation training) in ti,ab)
13. ((therapeutic communit* or motivational interview* or motivational enhance* or counseling or counselling or psychotherapy or
cognitive behavi*) in ti,ab)
14. ((work ethic or drug education or tasc or treatment accountability) in ti,ab)
15. ((asro or addressing substance or pasro or prisons addressing or acupuncture or shock or boot camp*) in ti,ab)
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16. ((arrest referral* or diversion or dtto or dttos or drug treatment or carat or carats or counseling assessment or combined orders)
in ti,ab)
17. ((residential program* or residential scheme* or residential service*) in ti,ab)
18. ((syringe exchange or dual diagnosis or narcotics anonymous or self help or selfhelp or outreach or bail support) in ti,ab)
19. ((drug-free or drug free or peer support or evaluation* or urinalysis or drug testing or drug use screen* or rehabilitation or discrete
service* or discrete program*) in ti,ab)
20. ((aftercare or after care or brief solution or brief intervention* or 12 step* or twelve step* or minnesota program* or needle
exchange or nes) in ti,ab)
21. ((trigger* or coping skills or anger management or group work or lifestyle modif* or high intensity training or resettlement or
throughcare) in ti,ab)
22. ((self management or interpersonal skills or social skills or basic skills or relapse prevent* or prevent* relapse or craving reduc* or
reduc* craving) in ti,ab)
24. ((rational-emotive or rational emotive or family relationship therap* or community reinforcement or self monitoring or goal
setting or self control training) in ti,ab)
25. #1 or #2
26. #3 or #4 or #5 or #6 or #7 or #8 or 9 or #10 or #11
27. #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24
28. 25 and #26 and #27
Appendix 13. Criminal Justice Abstracts search strategy
CJA search
1. (substance abuse* or substance misuse* or substance use or substance users) in ti,ab,de
2. substance related in ti,ab,de
3. drug related in ti,ab,de
4. (drug dependenc* or drug abuse* or drug misuse* or drug use or drug users or drug addiction) in ti,ab,de
5. (narcotics use or narcotics users or narcotics abuse* or narcotics misuse* or chemical dependenc*) in ti,ab,de
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6. (opiates or heroin or crack or cocaine or amphetamines or addict or addicts or addicted or dependence disorder* or drug involved)
in ti,ab,de
7. (designer drugs or street drugs or polydrug misuse* or polydrug abuse*) in ti,ab,de
8. #1 or #2 or #3 or #4 or #5 or #6 or #7
9. ((antagonist near prescri*) or diamorphine or naltrexone) in ti,ab,de
10(therapeutic communit* or (motivational near interview*)) in ti,ab,de
11. (motivational near enhancement) in ti,ab,de
12. (counselling or counseling) in ti,ab,de
13. (psychotherap* or cognitive behav* or behav* therap* or (moral near training)) in ti,ab,de
14. (cognitive restructuring or (assertiveness near train*) or relaxation training) in ti,ab,de
15. (rational emotive or family relationship therap*) in ti,ab,de
16. (community reinforcement or self monitoring or goal setting or goalsetting) in ti,ab,de
17. (self control near training) in ti,ab,de
18. (self management) in ti,ab,de
19. (interpersonal skills near training) in ti,ab,de
20. ((social skills or basic skills) near training) in ti,ab,de
21. ((relapse near prevent*) or (craving near reduc*)) in ti,ab,de
22. (trigger* or coping skills or anger management or group work or (lifestyle near modif*)) in ti,ab,de
23. (high intensity training or resettlement or throughcare or aftercare or after care) in ti,ab,de
24. (brief solution* or brief intervention*) in ti,ab,de
25. (minnesota in ti,ab) in ti,ab,de
26. (12 step* or twelve step*) in ti,ab,de
27. (needle exchange or nes or syringe exchange) in ti,ab,de
28. (dual diagnosis or narcotics anonymous or self help or selfhelp or outreach) in ti,ab,de
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29. (bail support or bail program* or arrest referral* or diversion or dtto* or drug treatment) in ti,ab,de
30. (carat or counselling assessment or counseling assessment) in ti,ab,de
31. (combined order* or drug free wing* or drug free environment* or peer support) in ti,ab,de
32. (user evaluations or urinalys* or urinanalys* or drug test* or rehab* or discrete service*) in ti,ab,de
33. (discrete program* or residential program* or residential scheme*) in ti,ab,de
34. (asro or addressing substance*) in ti,ab,de
35. (pasro or prisons addressing) in ti,ab,de
36. (acupuncture or shock or boot camp or boot camps or work ethic camp*) in ti,ab,de
37. (drug education or tasc or treatment accountability) in ti,ab,de
38. (detoxification or detox or methadone maintenance or (methadone near prescri*)) in ti,ab,de
39. #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26
or #27 or #28 or #29
40. #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39
41. #39 or #40
42. #8 and #41
9. #42 and (PY > “1979”)
Appendix 14. Criteria for assessing risk of bias
Item Judgment Description
1. Random sequence generation (selection
bias)
Low risk The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimization
High risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability of
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the intervention
Unclear risk Insufficient information about the sequence generation process to permit
judgement of low or high risk
2. Allocation concealment (selection bias) Low risk Investigators enrolling participants could not foresee assignment because
one of the following, or an equivalentmethod, was used to conceal alloca-
tion: central allocation (including telephone, web-based, and pharmacy-
controlled, randomisation); sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed envelopes
High risk Investigators enrolling participants could possibly foresee assignments
because one of the following method was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or
not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure
Unclear risk Insufficient information to permit judgement of low or high risk This
is usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgement
3. Blinding of participants and providers
(performance bias)
Objective outcomes
Low risk No blinding or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding;
Blinding of participants and key study personnel ensured, and unlikely
that the blinding could have been broken
4. Blinding of participants and providers
(performance bias)
Subjective outcomes
Low risk Blinding of participants and providers and unlikely that the blinding
could have been broken;
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding;
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk;
5. Blinding of outcome assessor (detection
bias)
Objective outcomes
Low risk Noblinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding;
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
6.Blinding of outcome assessor (detection
bias)
Subjective outcomes
Low risk Noblinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding;
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
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High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding;
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk;
7. Incomplete outcome data (attrition bias)
For all outcomes except retention in treat-
ment or drop out
Low risk No missing outcome data;
Reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias);
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups;
For dichotomous outcome data, the proportion of missing outcomes
comparedwith observed event risk not enough tohave a clinically relevant
impact on the intervention effect estimate;
For continuous outcome data, plausible effect size (difference inmeans or
standardized difference in means) among missing outcomes not enough
to have a clinically relevant impact on observed effect size;
Missing data have been imputed using appropriate methods
All randomised patients are reported/analysed in the group they were
allocated to by randomisation irrespective of non-compliance and co-
interventions (intention to treat)
High risk Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across
intervention groups;
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant
bias in intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means
or standardized difference in means) among missing outcomes enough
to induce clinically relevant bias in observed effect size;
‘As-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomisation;
Unclear risk Insufficient information to permit judgement of low or high risk (e.g.
number randomised not stated, no reasons for missing data provided;
number of drop out not reported for each group);
8 Selective reporting (reporting bias) Low risk The study protocol is available and all of the study’s pre-specified (primary
and secondary) outcomes that are of interest in the review have been
reported in the pre-specified way;
The study protocol is not available but it is clear that the published reports
include all expected outcomes, including those that were pre-specified
(convincing text of this nature may be uncommon)
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High risk Not all of the study’s pre-specified primary outcomes have been reported;
One or more primary outcomes is reported using measurements, analysis
methods or subsets of the data (e.g. sub scales) that were not pre-specified;
One or more reported primary outcomes were not pre-specified (unless
clear justification for their reporting is provided, such as an unexpected
adverse effect);
One ormore outcomes of interest in the review are reported incompletely
so that they cannot be entered in a meta-analysis;
The study report fails to include results for a key outcome that would be
expected to have been reported for such a study
Unclear risk Insufficient information to permit judgement of low or high risk
9. Other bias * Low risk Evidence to suggest other problems identified with the study which
might threaten the validity of the random allocation, attrition or data
integrity and results of the trial
High risk Evidence to suggest that the trial might be underpowered/problems with
the random allocation process leading to potential self selection bias/
issues of analysis not conducted using intent to treat analysis or evidence
of missing data. Concerns of attrition and measurement error including
reliance on self report measures
Unclear risk insufficient information to permit judgement of low or high risk
WH A T ’ S N E W
Last assessed as up-to-date: 31 May 2014.
Date Event Description
2 March 2015 New citation required and conclusions have changed In the previous version pharmacological interventions for
drug-using offenders appeared to reduce overall subsequent
drug use and criminal activity (but to a lesser extent), while
with the introduction of new studies agonist treatments did
not seem effective in reducing drug use or criminal activity
29 July 2014 New search has been performed This latest update reflects an additional four new trials (and
one ongoing trial) with new follow-up data on two existing
trials with searches conducted up until May 2014
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H I S T O R Y
Review first published: Issue 12, 2013
Date Event Description
27 January 2014 Amended Plain language summary title correction
16 July 2012 New search has been performed This review has been updated using searches to 21March
2013. The review represents one in a family of four re-
views. The other reviews cover non- pharmacological in-
terventions for drug-using offenders and interventions
for drug-using female offenders and offenders with co-
occurring mental illness. This new review of pharmaco-
logical interventions with drug-using offenders contains
17 randomised controlled trials. Six of the 17 trials are
awaiting classification for the review; the remaining 11
trials represent a total of 2,678 participants
2 March 2012 New search has been performed The updated edit of this review produced a new docu-
ment with additional findings reflecting searches up to
11 November 2011. Five new review authors have been
added to this version of the review, including Steven
Duffy, Rachael McCool, Matthew Neilson, Catherine
Hewitt and Marrissa Martyn-St James
19 May 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Searches were constructed and conducted by DF. Three independent review authors inspected the search hits by reading the titles and
abstracts (AEP, MN, RW). Each potentially relevant study located in the search was obtained as a full article and was independently
assessed for inclusion by two review authors. In the case of discordance, a third independent review author arbitrated. Where it was
not possible to evaluate the study because of language problems or missing information, the studies were classified as ’translation/
information required to determine decision’ until a translation or further details were provided. Four review authors conducted data
extraction for the papers (MM-SJ, JMG, RW, and MN), and review author CG conducted data extraction and a narrative summary
of the cost-effectiveness studies. The results were compiled and organised by MM-ST, MN, CH, RW and AEP, and all eight authors
contributed towards the final draft text.
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S O U R C E S O F S U P P O R T
Internal sources
• Reviewer from Cochrane Drugs and Alcohol Group, Other.
A reviewer from the Drugs and Alcohol Group provided the researchers with the results of a search strategy for three databases
External sources
• The Department of Health funded the original review, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original review Perry 2006 has been split up into different reviews and so there is no dedicated protocol for this particular review
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Criminals; Buprenorphine [therapeutic use];Heroin [therapeutic use];Methadone [therapeutic use];Naltrexone [analogs&derivatives;
therapeutic use]; Narcotics [therapeutic use]; Randomized Controlled Trials as Topic; Substance-Related Disorders [∗drug therapy]
MeSH check words
Adult; Female; Humans; Male
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